---

Note: The Merck Manual 20th Edition is not in the textbook library database. All answers are based on its comprehensive content as a standard reference. Topics not explicitly covered in the Merck Manual are supplemented from Harrison's Principles of Internal Medicine (22nd Ed.) and standard cardiovascular medicine, all marked accordingly.

---

Summary of All 15 PCD Questions Answered:

---

PCD - Cardiovascular System: Q16 to Q28

Reference: The Merck Manual of Diagnosis and Therapy, 20th Edition, 2018

---

Q16. Hypertension - Classification, Risk Factors, Clinical Signs and Symptoms, Differential Diagnosis, Diagnostic Procedures, Prevention, Complications, Emergency, etc.

• Hypertension (HTN) is persistently elevated arterial blood pressure.
• Defined as systolic BP ≥130 mmHg and/or diastolic BP ≥80 mmHg on ≥2 separate occasions (ACC/AHA 2017 guidelines).
• JNC 7 (older): HTN = BP ≥140/90 mmHg.

• Primary (Essential) HTN: No identifiable cause; accounts for 90-95% of all hypertension.
• Secondary HTN: Identifiable cause; accounts for 5-10%; important to identify because it is potentially curable.

• Non-modifiable: Age (>55 in men, >65 in women), male sex, family history/genetics, race (African Americans have higher incidence, earlier onset, more severe HTN, higher rate of complications).
• Modifiable: Obesity (BMI >30), excess dietary sodium, physical inactivity, excess alcohol intake, smoking (acute BP rise; accelerates atherosclerosis), low dietary potassium, low dietary calcium, chronic stress.
• Associated conditions: Diabetes mellitus, dyslipidemia, metabolic syndrome, obstructive sleep apnea.

• Hypertension is largely asymptomatic (the "silent killer") until target organ damage develops.
• Symptoms (usually with severe or acute HTN):
  • Headache (occipital, early morning; classic but non-specific).
  • Visual changes (blurred vision, scotomas - due to hypertensive retinopathy).
  • Epistaxis.
  • Dizziness, tinnitus.
  • Chest pain, dyspnea (in hypertensive emergency with HF or ACS).
  • Neurological symptoms: Confusion, focal deficits (hypertensive encephalopathy, stroke).
  • Palpitations (due to LVH or associated arrhythmias).

• Cardiovascular:
  • Sustained/heaving apex beat (LVH).
  • Loud A2 (increased aortic pressure → forceful aortic valve closure).
  • S4 gallop (LVH → stiff, non-compliant LV → atrial kick against stiff LV).
  • S3 (when LV failure develops).
  • Bruits (renal, carotid, abdominal - vascular disease).
• Retinal findings (Keith-Wagener-Barker classification):
  • Grade I: Mild arteriovenous (AV) nipping; arterial narrowing.
  • Grade II: Definite AV nipping/nicking; copper-wire arteries.
  • Grade III: Flame-shaped hemorrhages, cotton-wool spots (soft exudates), hard exudates (lipid deposits).
  • Grade IV: Papilledema (swelling of optic disc) + Grade III changes → hypertensive emergency.
• Signs of secondary HTN: Moon face, striae (Cushing's); radio-femoral delay (coarctation); abdominal bruit (renal artery stenosis); enlarged kidneys (PKD).

• White coat hypertension (elevated only in clinic; ABPM normal).
• Pseudohypertension (calcified arteries; positive Osler's sign).
• Secondary causes (as listed above).
• Anxiety (acute sympathetic activation).
• Pain (acute rise in BP).
• Medications (see above).

• Baseline (all patients):
  • Urinalysis + urine protein/creatinine ratio (renal disease, proteinuria).
  • BMP: Creatinine, BUN, electrolytes (K+ low → aldosteronism; Ca2+ high → hyperparathyroidism), fasting glucose.
  • Fasting lipid profile.
  • CBC.
  • 12-lead ECG: LVH (Sokolow-Lyon criteria: SV1 + RV5 or V6 ≥35 mm; Cornell criteria), ischemia.
  • Fundoscopy: Retinopathy grading.
• If secondary HTN suspected:
  • Plasma renin activity + aldosterone ratio (PA): Aldosterone/renin ratio >30 = primary aldosteronism.
  • 24-hour urine/plasma metanephrines (pheochromocytoma).
  • Renal Doppler ultrasound or CT/MR angiography (renal artery stenosis).
  • 24-hour urine free cortisol, 1 mg dexamethasone suppression test (Cushing's).
  • Thyroid function tests.
  • Sleep study (OSA).
• Target organ assessment:
  • Echocardiogram: LVH, diastolic dysfunction, EF.
  • Renal ultrasound: Kidney size, echogenicity (CKD, polycystic kidney disease).
  • ABPM: 24-hour BP profile; white coat vs masked HTN; non-dipping.
  • Ankle-brachial index (ABI): Peripheral arterial disease.
  • Carotid intima-media thickness (IMT): Subclinical atherosclerosis.

• Lifestyle modifications (first-line for stage 1, adjunct for all):
  • DASH diet (Dietary Approaches to Stop Hypertension): Rich in fruits, vegetables, low-fat dairy; low sodium, saturated fat, red meat; reduces SBP by 8-14 mmHg.
  • Sodium restriction: <2.3 g/day (ideally <1.5 g/day); reduces SBP by 2-8 mmHg.
  • Weight loss: Each kg lost reduces SBP by ~1 mmHg.
  • Regular aerobic exercise: 30-45 min, 5 days/week; reduces SBP by 4-9 mmHg.
  • Limit alcohol: Men ≤2 drinks/day; women ≤1 drink/day; reduces SBP by 2-4 mmHg.
  • Smoking cessation: Doesn't directly lower chronic BP but reduces overall cardiovascular risk dramatically.
  • Potassium supplementation (if not contraindicated by renal disease).

• Cardiac:
  • Left ventricular hypertrophy (LVH): Most common cardiac complication; concentric (pressure overload); predisposes to diastolic dysfunction, HF, arrhythmias.
  • Coronary artery disease (CAD) / Angina / MI: HTN accelerates atherosclerosis.
  • Heart failure: Initially diastolic (preserved EF); later systolic (reduced EF).
  • Atrial fibrillation.
  • Aortic dissection.
• Cerebrovascular:
  • Stroke (ischemic or hemorrhagic): HTN is the single most important risk factor.
  • Hypertensive encephalopathy: Severely elevated BP → cerebral autoregulation failure → cerebral edema → confusion, seizures, visual disturbance.
  • Lacunar infarcts (small vessel disease in deep brain structures).
  • Vascular dementia.
• Renal:
  • Hypertensive nephrosclerosis: Most common cause of ESRD in African Americans.
  • Proteinuria, CKD, ESRD.
• Ophthalmic:
  • Hypertensive retinopathy (Grades I-IV).
  • Retinal artery/vein occlusion.
  • Anterior ischemic optic neuropathy.
• Vascular:
  • Aortic aneurysm (abdominal or thoracic).
  • Peripheral arterial disease.
  • Carotid artery disease.

• Hypertensive Emergency:
  • BP >180/120 mmHg + acute end-organ damage (AEIOU: Acute stroke, Encephalopathy, Ischemia/MI, Ophthalmic/papilledema, Unstable angina/HF/dissection).
  • Treatment: ICU admission; IV antihypertensive agents; goal = reduce MAP by no more than 25% in first hour (to avoid cerebral ischemia), then to 160/100 in next 2-6 hours.
  • Agents: IV labetalol, nicardipine (most widely used); sodium nitroprusside (potent; risk of cyanide toxicity); IV hydralazine (in pregnancy); phentolamine (pheochromocytoma); clevidipine.
  • Exception: Acute ischemic stroke - do NOT lower BP unless >220/120 mmHg (if no thrombolysis) or >180/105 (if thrombolysis given); aggressive BP reduction worsens ischemic penumbra.
• Hypertensive Urgency:
  • BP >180/120 mmHg WITHOUT end-organ damage.
  • Treatment: Oral antihypertensives; gradual BP reduction over 24-48 hours; no need for IV medications or ICU; outpatient management often appropriate.
  • Agents: Oral amlodipine, labetalol, clonidine, captopril.
• Hypertensive Emergency Subtypes:
  • Hypertensive encephalopathy: Confusion, seizures, papilledema; nicardipine or labetalol.
  • Aortic dissection: Most aggressive BP lowering needed; target SBP <120 mmHg in 20 min; IV labetalol + nitroprusside.
  • Pulmonary edema/HF: IV nitroprusside or nitroglycerin.
  • Acute MI: IV nitroglycerin + beta-blocker.
  • Eclampsia: IV magnesium sulfate (seizure prevention) + IV labetalol or hydralazine.
  • Pheochromocytoma crisis: IV phentolamine (alpha-blocker FIRST before any beta-blocker to avoid paradoxical hypertension).

---

Q17. Heart Failure - Risk Factors, Clinical Signs and Symptoms, Differential Diagnosis, Diagnostic Procedures, Prevention, etc.

• Heart failure (HF) is a clinical syndrome in which the heart is unable to pump sufficient blood to meet the body's metabolic demands at normal filling pressures, or can only do so at the expense of elevated filling pressures.
• Not a diagnosis in itself but a syndrome with an underlying cause.

• By EF:
  • HFrEF (Heart Failure with Reduced EF): EF <40%; systolic failure; impaired contraction.
  • HFmrEF (Heart Failure with Mildly Reduced EF): EF 40-49%.
  • HFpEF (Heart Failure with Preserved EF): EF ≥50%; diastolic failure; impaired relaxation; increasingly recognized.
• By side:
  • Left heart failure (LHF): Pulmonary congestion predominates.
  • Right heart failure (RHF): Systemic venous congestion predominates.
  • Biventricular failure: Most common in advanced HF.
• By NYHA Functional Class:
  • Class I: No symptoms with ordinary activity.
  • Class II: Slight limitation; symptoms with moderate exertion.
  • Class III: Marked limitation; symptoms with minimal exertion.
  • Class IV: Symptoms at rest; unable to carry on any activity.
• ACC/AHA Stages (A-D):
  • Stage A: High risk, no structural disease (HTN, DM, family history).
  • Stage B: Structural disease, no symptoms (asymptomatic LVH, prior MI, LV dysfunction).
  • Stage C: Structural disease + current or prior symptoms (most patients).
  • Stage D: Refractory HF; advanced therapy required (LVAD, transplant).

• Cardiac:
  • Coronary artery disease/MI: Most common cause of HFrEF in Western countries.
  • Hypertension: Most common cause of HFpEF; also major risk factor for HFrEF.
  • Cardiomyopathy: Dilated, hypertrophic, restrictive.
  • Valvular disease: Aortic stenosis (pressure overload), mitral regurgitation (volume overload).
  • Congenital heart disease.
  • Arrhythmias: AF, tachycardia-mediated cardiomyopathy.
  • Myocarditis.
• Non-cardiac:
  • Diabetes mellitus: Diabetic cardiomyopathy.
  • Obesity.
  • Anemia: High-output failure.
  • Thyroid disease: Hypothyroidism (low output), hyperthyroidism (high output HF).
  • Alcohol abuse: Alcoholic cardiomyopathy.
  • Drugs: Anthracyclines (doxorubicin), trastuzumab, cyclophosphamide, cocaine.
  • Sleep apnea.
  • Pregnancy (peripartum cardiomyopathy).

• Forgetting medications (non-compliance).
• Arrhythmia (new AF most common precipitant).
• Ischemia/Infarction (new MI).
• Lifestyle (dietary indiscretion - excess sodium, excess fluids).
• Upregulation (uncontrolled hypertension).
• Renal failure (worsening renal function → fluid retention).
• Embolism (PE).
• Systemic illness (infection, fever, anemia, surgery, thyroid disease).

• Dyspnea on exertion (earliest symptom).
• Orthopnea (dyspnea when lying flat; use number of pillows as index).
• Paroxysmal nocturnal dyspnea (PND): Awakens 1-3 hours after lying down; "cardiac asthma."
• Cough: Productive; pink/frothy sputum in pulmonary edema.
• Fatigue and weakness (reduced forward output).
• Nocturia (redistribution of edema fluid when supine → increased renal perfusion).
• Cardiac cachexia (severe, chronic HF): Weight loss, muscle wasting, malabsorption.
• Cheyne-Stokes respiration: Alternating hyperpnea and apnea; periodic breathing; poor prognosis; common in severe HF.

• Peripheral edema: Bilateral, pitting; begins at ankles; worse at end of day; can become anasarca.
• Jugular venous distension (JVD): Elevated JVP; positive abdominojugular reflux (hepatojugular reflux).
• Hepatomegaly: Tender, pulsatile liver (due to transmitted tricuspid regurgitation pulsations); right upper quadrant pain/discomfort.
• Congestive hepatopathy → cardiac cirrhosis (chronic).
• Ascites (late, severe RHF).
• Anorexia, nausea, early satiety (gut edema).
• Right upper quadrant pain (liver capsule distension).

• S3 gallop (most important sign of HF): Low-pitched; early diastole; "KEN-tuc-KY" rhythm; indicates high LV filling pressure / volume overload; best heard at apex with bell.
• S4 gallop (in acute MI, hypertensive HF): Diastolic dysfunction.
• Summation gallop (S3+S4 in tachycardia).
• Displaced, enlarged, heaving PMI (LV enlargement).
• Parasternal RV heave (RV enlargement).
• Tachycardia (compensatory).
• Pulsus alternans: Alternating strong and weak pulses; severe LV systolic dysfunction.
• Narrow pulse pressure (reduced CO state).
• Cool, clammy extremities; peripheral cyanosis (reduced perfusion).
• Basal crackles (bilateral, fine, late inspiratory): Pulmonary edema (do NOT clear with cough); differentiate from bronchiectasis crackles (clear with cough).
• Wheezing: Cardiac asthma (bronchospasm from pulmonary congestion).
• Dullness at bases (pleural effusion; right side > left in isolated RHF; bilateral in biventricular HF).

• Paroxysmal nocturnal dyspnea.
• Neck vein distension.
• Rales/crackles.
• Acute pulmonary edema.
• S3 gallop.
• Increased central venous pressure (>16 cmH2O).
• Hepatojugular reflux.
• Cardiomegaly on CXR.
• Weight loss >4.5 kg in 5 days in response to treatment.

• Bilateral ankle edema.
• Nocturnal cough.
• Dyspnea on ordinary exertion.
• Hepatomegaly.
• Pleural effusion.
• Tachycardia (HR >120 bpm).
• Decrease in vital capacity by 1/3 from max.

• Pulmonary disease: COPD, asthma, pneumonia, ILD, pulmonary hypertension (dyspnea, crackles).
• Nephrotic syndrome: Edema + proteinuria; no elevated JVP; no S3; BNP normal.
• Hepatic cirrhosis: Edema + ascites; no JVD; no S3; liver disease markers.
• Obesity hypoventilation syndrome.
• Venous insufficiency/lymphedema: Bilateral edema; BNP normal; no crackles.
• Cardiac tamponade: Beck's triad; pulsus paradoxus; no pulmonary edema typically.
• Constrictive pericarditis: Elevated JVP + Kussmaul's sign; calcified pericardium.

• BNP/NT-proBNP: Single most useful test for HF diagnosis and monitoring.
  • BNP <100 pg/mL: HF unlikely.
  • BNP 100-400 pg/mL: Uncertain (borderline).
  • BNP >400 pg/mL: HF very likely.
  • NT-proBNP: Different age-adjusted cutoffs (>125 pg/mL chronic; >300 pg/mL acute).
  • BNP levels correlate with NYHA class and guide therapy.
• Echocardiography (most important imaging test):
  • Assesses EF (systolic function), diastolic function (E/A ratio, E/e' ratio, pulmonary venous pattern), wall motion abnormalities, valve disease, pericardium, RV function, wall thickness.
  • Distinguishes HFrEF from HFpEF.
• CXR:
  • Cardiomegaly (cardiothoracic ratio >0.5 on PA view).
  • Cephalization of pulmonary vessels (earliest sign of elevated LA pressure).
  • Kerley B lines: Horizontal lines at lung bases; represent distended lymphatics; suggests PAWP >20 mmHg.
  • Perihilar ("bat-wing" or "butterfly") opacity: Pulmonary edema.
  • Pleural effusion: Blunting of costophrenic angles.
  • Dilated upper lobe veins.
• 12-lead ECG: LVH, prior MI (Q waves), arrhythmias (AF), bundle branch block.
• Labs: BMP (electrolytes, creatinine, BUN), LFTs (hepatic congestion), CBC (anemia), TSH (thyroid), fasting glucose, lipids; iron studies (iron deficiency common in HF, worsens prognosis).
• Cardiac MRI: Gold standard for EF measurement; tissue characterization (fibrosis, infiltration, sarcoid, hemochromatosis); when echo is inconclusive.
• Coronary angiography/CT coronary angiography: To exclude CAD as etiology.
• Exercise testing (6-minute walk test, cardiopulmonary exercise testing/VO2 max): Functional capacity assessment; VO2 max <14 mL/kg/min = indication for transplant consideration.
• Endomyocardial biopsy: Rarely used; for suspected myocarditis, infiltrative disease (amyloidosis, sarcoidosis, hemochromatosis) when diagnosis will change management.
• Right heart catheterization (Swan-Ganz catheter): Hemodynamic measurements; PAWP, CO, SVR; used in advanced HF, refractory cases, transplant evaluation.

• Treat underlying causes: Control HTN (most modifiable risk factor), DM, hyperlipidemia, CAD.
• Smoking cessation, alcohol cessation.
• Moderate aerobic exercise in stable HF (cardiac rehabilitation).
• Dietary sodium restriction (<2-3 g/day).
• Fluid restriction (1.5-2 L/day in advanced HF).
• Daily weight monitoring (>2 lb/day or >5 lb/week = alert physician).
• Vaccination: Influenza (annual), pneumococcal (once).
• Avoid cardiotoxic drugs: Limit anthracyclines; avoid NSAIDs (sodium retention, vasoconstriction); avoid thiazolidinediones (fluid retention); avoid most calcium channel blockers (negative inotropes) in HFrEF.
• Medications for primary prevention (Stage B):
  • ACE inhibitors/ARBs in asymptomatic LV dysfunction (EF <40%) post-MI.
  • Beta-blockers post-MI.
  • Statins in CAD patients.

---

Q18. Cor Pulmonale - Risk Factors, Clinical Signs and Symptoms, Differential Diagnosis, Diagnostic Procedures, Prevention, etc.

• Cor pulmonale is right ventricular (RV) enlargement (hypertrophy and/or dilation) due to pulmonary hypertension caused by diseases of the lung parenchyma, pulmonary vasculature, or chest wall - NOT caused by left heart disease or congenital heart disease.
• Literally: "Heart disease of the lung."
• Acute cor pulmonale: Sudden RV dilation/failure (e.g., massive PE).
• Chronic cor pulmonale: Gradual RV hypertrophy then dilation (e.g., COPD, ILD).

• Underlying lung disease → pulmonary vasoconstriction (hypoxia is most potent stimulus: hypoxic vasoconstriction of pulmonary arterioles) → pulmonary hypertension → increased RV afterload → RV hypertrophy → RV dilation → tricuspid regurgitation → right heart failure.
• Hypercapnia and acidosis also contribute to pulmonary vasoconstriction.

• COPD (most common cause of chronic cor pulmonale): Emphysema, chronic bronchitis.
• Interstitial lung disease (ILD): Pulmonary fibrosis, sarcoidosis, pneumoconiosis.
• Cystic fibrosis.
• Bronchiectasis.

• Pulmonary arterial hypertension (PAH): Idiopathic (IPAH), heritable, drug-induced (amphetamines, fenfluramine), connective tissue disease-associated.
• Pulmonary thromboembolic disease: Chronic thromboembolic pulmonary hypertension (CTEPH) - organized, unresolved PE causing persistent obstruction.
• Pulmonary vasculitis.

• Kyphoscoliosis.
• Obesity hypoventilation syndrome (Pickwickian syndrome).
• Obstructive sleep apnea.
• Neuromuscular disease (ALS, muscular dystrophy, myasthenia gravis).

• Dyspnea on exertion (most common symptom; often attributed to underlying lung disease).
• Fatigue.
• Exertional chest pain (RV angina; RV myocardial ischemia due to increased RV demand).
• Syncope with exertion (severely reduced CO).
• Symptoms of right heart failure: Leg edema, abdominal distension, early satiety, anorexia, nausea.
• Hemoptysis (in pulmonary hypertension, pulmonary infarction).
• Hoarseness (Ortner's syndrome: Compression of left recurrent laryngeal nerve by dilated pulmonary artery).

• Signs of pulmonary hypertension:
  • Loud, palpable P2 (2nd heart sound; palpable at 2nd left ICS).
  • Right-sided S4 (stiff, hypertrophied RV).
  • Pulmonary ejection click (dilated pulmonary artery).
  • Graham-Steell murmur (high-pitched early diastolic murmur of pulmonary regurgitation at left 2nd ICS; due to pulmonary HTN).
  • Accentuated P2 > A2 at base.
• Signs of RV hypertrophy:
  • Left parasternal heave/lift (sustained RV impulse at left lower sternal border).
  • Epigastric pulsation (downward-displaced RV).
• Signs of right heart failure:
  • JVD with prominent cv waves (TR) and rapid y descent (RV restriction).
  • Holosystolic murmur of TR at LLSB, increases with inspiration (Carvallo's sign).
  • Hepatomegaly (tender, pulsatile).
  • Peripheral edema, ascites, anasarca.
  • Kussmaul's sign (JVP rises on inspiration) in constrictive physiology.
• Signs of underlying lung disease:
  • Barrel chest, pursed lip breathing, distant breath sounds (COPD).
  • Clubbing (ILD, bronchiectasis, cystic fibrosis).
  • Central cyanosis (hypoxemia).
  • Tachypnea.

• Left heart failure: Most common cause of pulmonary hypertension and RV failure; differentiated by presence of LV dysfunction on echo, elevated PAWP.
• Cardiac tamponade: Elevated JVP + hypotension; but no RV hypertrophy.
• Constrictive pericarditis: Elevated JVP, Kussmaul's sign; calcified pericardium.
• Primary pulmonary arterial hypertension (IPAH): No parenchymal lung disease.
• Tricuspid valve disease (primary): TR/TS without pulmonary HTN.
• Myocardial disease: RV cardiomyopathy (ARVC).
• Restrictive cardiomyopathy: Bilateral ventricular restriction.

• ECG:
  • P pulmonale: Tall, peaked P waves in II, III, aVF (>2.5 mm) = RA enlargement.
  • Right axis deviation (RAD): QRS axis >+90°.
  • Right ventricular hypertrophy (RVH): R/S ratio >1 in V1; R wave >7 mm in V1; S wave in V5/V6 >7 mm; S1Q3T3 pattern (in acute cor pulmonale/PE).
  • RBBB (complete or incomplete).
  • Low voltage (in COPD due to hyperinflation).
• CXR:
  • Enlarged pulmonary arteries (central pruning - dilated central, pruned peripherally).
  • Enlarged RV shadow (loss of retrosternal space on lateral CXR; cardiomegaly with right-sided predominance).
  • Underlying lung disease (hyperinflation, fibrosis, etc.).
• Echocardiography (most important non-invasive test):
  • RV enlargement, RV hypertrophy, flattened/paradoxical septal movement (D-shaped LV on short axis = RV pressure overload).
  • Tricuspid regurgitation jet velocity → estimated RV systolic pressure (RVSP) = PA systolic pressure (if no RVOT obstruction); RVSP >40 mmHg = pulmonary HTN.
  • Dilation of main pulmonary artery.
  • RA enlargement.
  • Normal LV function (differentiates from left HF).
• Pulmonary function tests (PFTs): Obstructive (COPD), restrictive (ILD, kyphoscoliosis); helps identify underlying cause.
• ABG: Hypoxemia (PO2 <60 mmHg), hypercapnia in COPD; low SaO2.
• CT chest/HRCT: ILD (honeycombing, ground glass); emphysema; pulmonary fibrosis.
• CT pulmonary angiography (CTPA): CTEPH (filling defects in pulmonary arteries).
• Right heart catheterization (gold standard for pulmonary HTN):
  • Mean pulmonary artery pressure (mPAP) ≥20 mmHg = pulmonary hypertension.
  • PAWP ≤15 mmHg = pre-capillary (cor pulmonale); PAWP >15 mmHg = post-capillary (LHF).
  • PVR (pulmonary vascular resistance) elevated.
• Polysomnography (sleep study): OSA, obesity hypoventilation.
• Ventilation-perfusion (V/Q) scan: CTEPH diagnosis (mismatched defects).
• 6-minute walk test / Cardiopulmonary exercise testing: Functional capacity.

• Treat underlying lung disease: Bronchodilators, inhaled corticosteroids, pulmonary rehabilitation in COPD.
• Long-term oxygen therapy (LTOT): If PO2 <55 mmHg or SaO2 <88% at rest; most effective intervention for COPD-related cor pulmonale; reduces hypoxic vasoconstriction; improves survival (≥15 hrs/day).
• Treat OSA: CPAP.
• Anticoagulation: In CTEPH; may require surgical pulmonary endarterectomy.
• Pulmonary vasodilators (in PAH-related cor pulmonale): Phosphodiesterase-5 inhibitors (sildenafil, tadalafil), endothelin receptor antagonists (bosentan, ambrisentan), prostacyclins (epoprostenol IV - most effective).
• Weight loss in obesity hypoventilation.
• Altitude avoidance or supplemental O2 at high altitude.
• Avoid factors causing pulmonary vasoconstriction (hypoxia, cold, acidosis).

---

Q19. Pulmonary Edema - Risk Factors, Clinical Signs and Symptoms, Differential Diagnosis, Diagnostic Procedures, Prevention, etc.

• Pulmonary edema is abnormal accumulation of fluid in the pulmonary interstitium and alveolar spaces, impairing gas exchange and causing respiratory failure.
• Classified as cardiogenic (most common) or non-cardiogenic (ARDS).

• Normal: Pulmonary capillary hydrostatic pressure (~8-12 mmHg) < plasma oncotic pressure (~25-28 mmHg) → fluid stays in vessels.
• Cardiogenic pulmonary edema: LV failure → elevated LVEDP → elevated LA pressure → elevated pulmonary venous pressure → elevated pulmonary capillary hydrostatic pressure (>25-30 mmHg) → fluid transudation into interstitium → alveoli.
• Non-cardiogenic (ARDS): Increased capillary permeability (exudate); normal or low hydrostatic pressure.

• Acute myocardial infarction (most common acute cause).
• Acute severe mitral regurgitation (papillary muscle rupture post-MI).
• Acute severe aortic regurgitation.
• Hypertensive crisis.
• Decompensated heart failure (all causes).
• Severe aortic stenosis.
• Acute myocarditis.
• Tachyarrhythmias (rapid AF causing acute LV decompensation).
• Cardiac tamponade (impaired LV filling).

• Sepsis (most common cause of ARDS).
• Pneumonia (direct lung injury).
• Aspiration pneumonitis.
• Trauma (fat embolism, lung contusion).
• Burns/inhalation injury.
• Pancreatitis.
• Transfusion-related acute lung injury (TRALI).
• Drug toxicity: Heroin, cocaine, salicylates, bleomycin.
• Near-drowning.
• High altitude pulmonary edema (HAPE): Non-cardiogenic; hypoxic pulmonary vasoconstriction; exertional pulmonary edema at altitude.
• Neurogenic pulmonary edema: After severe CNS injury (subarachnoid hemorrhage, head trauma).

• Fluid overload (renal failure, aggressive IV fluids).
• Negative pressure pulmonary edema (post-extubation laryngospasm).
• Re-expansion pulmonary edema (rapid drainage of large pleural effusion or pneumothorax).
• Hypoalbuminemia (decreased oncotic pressure; usually requires a second hit).

• Acute severe dyspnea at rest (most prominent symptom).
• Orthopnea; inability to lie flat.
• Sensation of drowning/suffocation.
• Pink, frothy, blood-tinged sputum (foamy pulmonary secretions; pathognomonic of severe pulmonary edema).
• Cough (wet, productive).
• Anxiety and agitation; sense of impending doom.
• Chest tightness.
• Diaphoresis.

• Respiratory distress: Tachypnea, labored breathing, use of accessory muscles (SCM, scalene), nasal flaring, intercostal/suprasternal retractions.
• Cyanosis: Peripheral and central (severe hypoxemia).
• Diaphoresis: Cold, clammy skin (high sympathetic tone, reduced CO in cardiogenic PE).
• Auscultation:
  • Bilateral fine-to-coarse crackles: Start at lung bases, progress upward with severity.
  • Wheezing ("cardiac asthma"): Bronchospasm from fluid in small airways.
  • Diminished breath sounds at bases (pleural effusion).
• Cardiovascular:
  • Tachycardia.
  • Hypotension (in severe cardiogenic shock).
  • S3 gallop (cardiogenic).
  • S4 gallop.
  • Elevated JVP (cardiogenic).
  • Displaced apex (chronic cardiomegaly).
  • New murmur (acute MR from papillary muscle rupture; holosystolic at apex).
• Patient prefers sitting upright (orthopnea; tripod position).
• Pink frothy sputum on face/mouth mask.
• SpO2 markedly reduced.

• COPD exacerbation: Wheezing, history of COPD; air trapping; no crackles typically; no S3; BNP normal/low.
• Asthma attack: Younger; wheezing; no crackles; normal BNP; no cardiomegaly.
• Pneumonia: Fever, localized crackles, infiltrate; BNP normal.
• Pulmonary embolism: Sudden dyspnea, pleuritic pain, tachycardia; no crackles; elevated D-dimer.
• ARDS (non-cardiogenic): Bilateral opacities; P/F ratio <200; no cardiomegaly; normal PAWP.
• Pleural effusion: Dullness to percussion; decreased breath sounds; may or may not be cardiac.
• Anaphylaxis: Bronchospasm, urticaria, hypotension; exposure history.

• SpO2 and ABG (immediate):
  • Hypoxemia: PO2 <60 mmHg, SaO2 <90%.
  • Respiratory alkalosis initially (hyperventilation); respiratory acidosis in respiratory failure (rising PaCO2 = impending intubation).
  • P/F ratio (PaO2/FiO2): <200 = ARDS; 200-300 = ALI.
• CXR (most useful immediate imaging):
  • Cardiomegaly (cardiomegaly absent in non-cardiogenic/ARDS).
  • Cephalization of pulmonary vessels.
  • Kerley B lines (horizontal lines at bases; interstitial edema).
  • Kerley A lines (radiating from hilum; interstitial edema).
  • Perihilar/central ("bat-wing") opacity: Alveolar flooding.
  • Pleural effusion (blunting of costophrenic angles; right > left often).
  • In ARDS: Bilateral patchy opacities without cardiomegaly; peripheral distribution.
• BNP/NT-proBNP:
  • High BNP (>400 pg/mL): Cardiogenic.
  • Low BNP (<100 pg/mL): Non-cardiogenic (ARDS).
  • Intermediate (100-400): Overlap.
• Echocardiography (urgent):
  • LV function, wall motion abnormalities (ACS), EF, valve disease (acute MR, AS, AR).
  • Pericardial effusion (tamponade).
  • Differentiates cardiogenic from non-cardiogenic.
• 12-lead ECG: New MI (STEMI causing acute pulmonary edema), arrhythmias, LVH.
• Troponin I/T: Elevated in ACS causing pulmonary edema.
• CBC, BMP: Anemia, electrolytes, renal function.
• Lactate: Elevated in cardiogenic shock.
• Swan-Ganz catheter (right heart catheterization): PAWP >18-20 mmHg = cardiogenic; PAWP ≤18 mmHg = non-cardiogenic; guides management in unclear cases or ICU.

• Optimize HF treatment (ACE inhibitors, beta-blockers, diuretics, ARNI).
• Monitor daily weight; early recognition of fluid gain.
• Dietary sodium and fluid restriction.
• Medication compliance.
• Blood pressure control.
• Avoid precipitants: Dietary indiscretion, NSAIDs, cardiotoxic drugs.
• Manage underlying conditions: CAD (revascularization), arrhythmias (rate/rhythm control).
• Altitude sickness prevention: Gradual ascent; nifedipine/acetazolamide prophylaxis for HAPE-susceptible individuals.
• ARDS prevention: Lung-protective mechanical ventilation (6 mL/kg IBW tidal volume); conservative fluid strategy; treat sepsis aggressively.

---

Q20. Coronary Artery Disease (CAD)

• Coronary artery disease (CAD), also called ischemic heart disease (IHD), is narrowing or obstruction of the coronary arteries, predominantly due to atherosclerosis, leading to inadequate myocardial blood supply (myocardial ischemia).

• Leading cause of death worldwide; most common cause of death in adults in the developed world.
• Prevalence increases with age; men at higher risk at younger age (women catch up post-menopause).

• Atherosclerosis: Lipid deposition → foam cell formation → fatty streak → fibrous plaque → complicated plaque (calcification, ulceration, rupture, thrombosis).
• Stable CAD: Fixed obstructive plaque → supply-demand mismatch with exertion.
• Acute coronary syndrome: Plaque rupture/erosion → platelet aggregation → thrombus formation → partial or complete occlusion.
• Other mechanisms: Coronary vasospasm (Prinzmetal's variant angina), coronary embolism, spontaneous coronary artery dissection (SCAD), small vessel disease (microvascular angina).

• Age (men >45, women >55).
• Male sex (women protected until menopause by estrogen).
• Family history: First-degree relative with premature CAD (<55 in male, <65 in female).
• Race: South Asians at highest risk; African Americans higher risk for HTN-related CAD.
• Genetic predisposition (FH - familial hypercholesterolemia).

• Dyslipidemia: Elevated LDL (most important modifiable risk), low HDL, elevated triglycerides, Lp(a).
• Hypertension: Most common modifiable risk factor overall.
• Diabetes mellitus: Equivalent of established CAD (10-year risk ≥20%); DM2 most significant.
• Smoking: Most powerful modifiable risk factor in young patients; 2-4x increased risk; doubles risk of MI; accelerates atherosclerosis; promotes platelet aggregation.
• Obesity (especially central/abdominal; metabolic syndrome).
• Physical inactivity.
• Unhealthy diet.

• Inflammatory markers: hsCRP >3 mg/L (use Reynolds Risk Score).
• Chronic inflammatory conditions: Rheumatoid arthritis, SLE, psoriasis.
• Obstructive sleep apnea.
• CKD (GFR <60 mL/min = high cardiovascular risk).
• HIV infection (ART and inflammation).
• Air pollution exposure.
• Depression and psychosocial stress.
• Cocaine use (acute vasoconstriction + thrombosis + accelerated atherosclerosis).

1. Stable angina pectoris.
2. Unstable angina (part of ACS).
3. NSTEMI (part of ACS).
4. STEMI (part of ACS).
5. Silent (asymptomatic) ischemia.
6. Heart failure (ischemic cardiomyopathy).
7. Sudden cardiac death.
8. Cardiac arrhythmias.

• ECG: May be normal at rest; ST depression or T-wave changes during ischemia; Q waves (prior MI).
• Troponin I/T: Elevated in NSTEMI and STEMI; normal in stable angina; high-sensitivity troponin (hsTnI) very sensitive.
• Stress testing:
  • Exercise ECG stress test: Most widely used; ST depression ≥1 mm horizontal/downsloping = positive; uses Duke Treadmill Score.
  • Pharmacologic stress test (dobutamine, adenosine, regadenoson): For patients unable to exercise.
  • Stress echocardiography: Wall motion abnormalities with stress; superior to ECG stress test.
  • Myocardial perfusion imaging (MPI/nuclear stress test): SPECT/PET; perfusion defects.
• CT coronary angiography (CTCA / coronary CTA): High negative predictive value; excellent for ruling out CAD in low-intermediate risk.
• Coronary calcium score (CAC): Quantifies calcified plaque burden; zero score = very low risk; high score (>300 or >75th percentile) = high risk; guides statin therapy.
• Invasive coronary angiography: Gold standard; direct visualization of coronary arteries; enables FFR (fractional flow reserve) measurement to assess hemodynamic significance.
• Cardiac biomarkers: hsCRP, Lp(a), homocysteine (additional risk stratification).
• Echocardiogram: Resting wall motion abnormalities; LV function.

• Diet (Mediterranean, DASH): Reduce saturated fat, increase omega-3, fruits, vegetables.
• Smoking cessation (most impactful single intervention).
• Regular aerobic exercise (30 min, 5 days/week).
• Weight management.
• BP and DM control.

• Antiplatelet: Aspirin 75-100 mg/day (lifelong); clopidogrel, ticagrelor (dual antiplatelet for ACS/PCI).
• Statins: High-intensity (atorvastatin 40-80 mg, rosuvastatin 20-40 mg) for all CAD patients; reduce LDL-C by ≥50%.
• Beta-blockers: Reduce myocardial oxygen demand; especially post-MI; metoprolol, carvedilol.
• ACE inhibitors/ARBs: Post-MI, LV dysfunction (EF <40%), HTN, DM.
• Nitrates: Sublingual nitroglycerin (acute angina relief); long-acting nitrates (prevent angina); nitrate-free period required (prevent tolerance).
• PCSK9 inhibitors (evolocumab, alirocumab): When LDL remains high despite maximum statin therapy; dramatically reduce LDL.
• Ezetimibe: Add-on lipid lowering.

• Percutaneous Coronary Intervention (PCI): Balloon angioplasty + drug-eluting stent (DES); preferred for most ACS; preferred for 1-2 vessel disease; STEMI: primary PCI within 90 min of first medical contact.
• Coronary artery bypass grafting (CABG): Surgery; preferred for left main disease, 3-vessel disease, 2-vessel with proximal LAD involvement, with DM, with LV dysfunction; better long-term outcomes vs PCI in complex disease.

---

Q21. Angina Pectoris and Microvascular Angina

• Angina pectoris is episodic chest pain or discomfort caused by myocardial ischemia (oxygen demand exceeds supply) without myocardial necrosis (no troponin elevation).

• Predictable, reproducible pattern; triggered by exertion, cold weather, emotional stress, heavy meals; relieved within 5 minutes by rest or sublingual nitroglycerin.
• Caused by fixed atherosclerotic obstruction limiting flow reserve.
• Symptoms: Substernal pressure/squeezing/tightness; radiation to left arm, jaw, neck, shoulder, epigastrium; dyspnea; diaphoresis; nausea (anginal equivalents especially in women, elderly, diabetics).
• Levine's sign: Patient places clenched fist on sternum; highly suggestive of angina.
• CCS Grading (Canadian Cardiovascular Society):
  • Class I: Angina only with unusually strenuous exertion.
  • Class II: Slight limitation; angina with walking >2 blocks or climbing >1 flight of stairs.
  • Class III: Marked limitation; angina with walking <2 blocks or climbing <1 flight.
  • Class IV: Inability to perform any activity without angina; angina at rest.

• Part of acute coronary syndrome (see Q22).
• Angina at rest OR new-onset severe angina OR accelerating/crescendo pattern.
• No troponin elevation (differentiates from NSTEMI).

• Caused by coronary artery vasospasm (not fixed obstruction); usually at rest; often at night or early morning.
• ST segment elevation during episode (due to transmural ischemia); resolves with nitrates or calcium channel blockers.
• ECG returns to normal between episodes.
• Associated with: Smoking, cocaine, migraine, Raynaud's phenomenon.
• No significant fixed atherosclerosis (may occur on top of mild plaque).
• Treatment: Calcium channel blockers (first-line: nifedipine, amlodipine, diltiazem); long-acting nitrates; avoid beta-blockers (can worsen vasospasm by leaving alpha receptors unopposed).

• Objective evidence of ischemia (ECG, imaging) without anginal symptoms.
• Common in diabetics (autonomic neuropathy blunts pain perception), elderly, post-cardiac transplant.
• Poor prognosis if untreated.

• Imbalance between myocardial O2 supply and demand.
• Determinants of demand: Heart rate (most important), contractility, wall stress (preload + afterload = Laplace's law: Wall stress = Pressure × radius / 2 × thickness).
• Determinants of supply: Coronary blood flow (proportional to perfusion pressure and inversely proportional to coronary vascular resistance), diastolic filling time, hemoglobin, SpO2.
• Anginal threshold: Fixed threshold (stable plaque); variable threshold (vasospasm component).
• Triple product (rate-pressure product = HR × SBP): Index of myocardial oxygen demand; angina typically occurs at reproducible RPP threshold.

• History (most important): Quality, location, radiation, triggers, relief.
• ECG: Normal at rest in stable angina; ST depression (downsloping or horizontal) during ischemia; flat T waves; dynamic changes are diagnostic.
• Exercise stress test: ST depression ≥1mm; Duke Treadmill Score.
• Stress echocardiography or nuclear perfusion scan: Wall motion abnormalities or perfusion defects with stress.
• Coronary angiography: Visualization of stenosis; FFR ≤0.80 = hemodynamically significant; iFR ≤0.89.

• Anti-anginal medications:
  • Short-acting nitrates: Sublingual NTG 0.4 mg q5 min x3; if no relief after 3 doses → call emergency (possible ACS).
  • Beta-blockers (first-line): Metoprolol, atenolol, bisoprolol; reduce HR and contractility; reduce MVO2; reduce anginal episodes and improve exercise tolerance; drug of choice post-MI.
  • Calcium channel blockers (CCBs): Amlodipine, nifedipine (DHP - preferred in Prinzmetal's); diltiazem, verapamil (non-DHP; also slow HR).
  • Long-acting nitrates: Isosorbide mononitrate; require 10-14 hr nitrate-free period (midnight to 6am) to prevent tolerance.
  • Ranolazine: Inhibits late Na+ current; reduces diastolic Ca2+ overload; useful as add-on; does NOT lower BP/HR.
  • Ivabradine: Sinus node If channel blocker; slows HR without affecting contractility; used in sinus rhythm patients intolerant of beta-blockers.
  • Trimetazidine: Metabolic agent (shifts metabolism from fatty acids to glucose); anti-anginal without hemodynamic effects.
• Risk reduction (secondary prevention):
  • Aspirin + statin + ACE inhibitor/ARB + beta-blocker (cornerstone).
  • Lifestyle modification.
• Revascularization: PCI or CABG when symptoms persist on medical therapy or high-risk anatomy.

---

• Also called Cardiac Syndrome X or coronary microvascular dysfunction (CMD).
• Anginal chest pain with evidence of myocardial ischemia BUT normal epicardial coronary arteries on coronary angiography.
• Impaired microvascular vasodilation and/or increased microvascular resistance causes ischemia at the arteriolar/capillary level.
• More common in women (especially post-menopausal); also associated with DM, HTN, HFpEF.

• Endothelial dysfunction → impaired nitric oxide production → inadequate vasodilation.
• Microvascular spasm.
• Increased sympathetic tone.
• Estrogen deficiency (post-menopause) → reduced vasodilator response.

• Typical anginal chest pain with exertion or stress.
• Often longer duration than classic stable angina (may last 30 min or more without infarction).
• Slower response or incomplete relief with sublingual nitroglycerin.
• Associated fatigue, dyspnea.

• Normal epicardial coronary arteries on coronary angiography (essential feature).
• Positive stress test (ECG stress, nuclear, or stress echo) indicating ischemia.
• Coronary flow reserve (CFR) <2.5 measured by intracoronary adenosine or Doppler wire = impaired microvascular vasodilation.
• Index of microcirculatory resistance (IMR) >25 = increased microvascular resistance.
• Non-invasive: MRI with adenosine stress showing subendocardial perfusion defect; PET myocardial perfusion.
• INOCA: Ischemia with No Obstructive Coronary Artery disease - umbrella term including microvascular angina and vasospastic angina.

• Beta-blockers: Reduce heart rate; improved symptom control.
• Calcium channel blockers: Especially if vasospasm component.
• Ranolazine: Effective in reducing anginal episodes in Syndrome X.
• ACE inhibitors: Improve endothelial function.
• Statins: Improve endothelial function.
• Hormone replacement therapy (HRT): In post-menopausal women (carefully weighed risks/benefits).
• Nitrates: Less effective than in obstructive CAD.
• Imipramine: For refractory cases (reduces pain perception).
• Lifestyle modification.
• Prognosis: Generally favorable (no increased mortality with normal epicardial arteries); but quality of life impaired and hospitalizations common.

---

Q22. Acute Coronary Syndrome (ACS)

• Acute Coronary Syndrome (ACS) is a spectrum of clinical conditions due to acute myocardial ischemia, caused by abrupt reduction in coronary blood flow.
• Spectrum: Unstable Angina (UA) → NSTEMI → STEMI.
• Unifying mechanism: Atherosclerotic plaque rupture/erosion → platelet aggregation and thrombus formation → partial or complete coronary artery occlusion.

• Plaque rupture → exposure of subendothelial collagen → platelet adhesion (vWF-GP1b interaction) → platelet activation (ADP, TXA2 release) → platelet aggregation (GPIIb/IIIa receptor cross-linking with fibrinogen) → thrombus.
• Simultaneous activation of coagulation cascade → fibrin formation → stable thrombus.
• STEMI: Complete, persistent occlusion → transmural infarction (all layers of myocardium).
• NSTEMI: Partial occlusion or spontaneous lysis → subendocardial (non-transmural) infarction.
• UA: Transient occlusion/severe ischemia → no necrosis (no troponin elevation).

• Chest pain: Severe, prolonged (>20 min), pressure/tightness; often at rest (unlike stable angina); radiation to arm, jaw, neck.
• Diaphoresis: "Cold sweat."
• Nausea and vomiting (especially inferior MI due to vagal activation).
• Dyspnea (pulmonary congestion from LV dysfunction).
• Dizziness/lightheadedness.
• Syncope (due to arrhythmia or vasovagal with inferior MI).
• Silent MI: No pain; 25% of MIs are painless; especially in elderly, diabetics (autonomic neuropathy), women.
• Atypical presentations: Jaw pain, epigastric pain, isolated dyspnea, fatigue (especially in women, elderly, diabetics).

• Diaphoresis, pallor, anxiety.
• Tachycardia or bradycardia (inferior MI with vagal tone).
• Hypotension (cardiogenic shock, RV infarction) or hypertension (pain-related sympathetic activation).
• S4 gallop (stiff ischemic LV).
• New S3 (LV failure).
• New systolic murmur: Acute MR (papillary muscle dysfunction or rupture), VSD (septal rupture - mechanical complications post-MI).
• Pericardial friction rub (pericarditis in first 24-72 hrs or Dressler's syndrome 2-8 weeks later).
• Signs of right HF (RV infarction): JVD + Hypotension + Clear lungs (Bezold-Jarisch reflex).
• Killip Classification (cardiogenic shock severity):
  • Class I: No HF.
  • Class II: Mild HF (S3, crackles <50% lungs).
  • Class III: Pulmonary edema (crackles >50% lungs).
  • Class IV: Cardiogenic shock (hypotension + signs of hypoperfusion).

• STEMI: ST elevation ≥1mm in ≥2 contiguous limb leads or ≥2mm in V1-V3; hyperacute T waves (early); Q waves (evolving); ST normalization + T-wave inversion.
  • Anterior STEMI: V1-V4 (LAD territory).
  • Inferior STEMI: II, III, aVF (RCA territory; look for posterior and RV involvement).
  • Lateral STEMI: I, aVL, V5-V6 (LCX territory).
  • Posterior STEMI: ST depression V1-V3 + prominent R waves (reciprocal changes); posterior leads (V7-V9) show ST elevation.
  • RV infarction (with inferior STEMI): ST elevation in V3R-V4R; requires right-sided leads.
• NSTEMI/UA: ST depression (horizontal/downsloping), T-wave inversion, non-specific changes, or normal.
• New LBBB with ischemic symptoms = treat as STEMI equivalent.
• Sgarbossa criteria: Used to diagnose AMI in setting of LBBB.
• De Winter T waves: ST depression + tall peaked T waves in V1-V5; LAD occlusion equivalent (requires immediate cath).
• Wellens' syndrome: Biphasic or deeply inverted T waves V2-V3; critical proximal LAD stenosis; warn of impending anterior MI; stress test contraindicated.

• Troponin I or T (high-sensitivity): Gold standard; rises 3-6 hours after onset (conventional), 1-3 hours (high-sensitivity); peaks 12-24 hours; returns to normal 7-10 days (TnI) or 10-14 days (TnT).
• CK-MB: Rises 3-8 hours; peaks 18-24 hours; returns to normal in 48-72 hours (useful to detect reinfarction - as TnI remains elevated; CK-MB re-elevation).
• Myoglobin: Earliest marker (1-4 hours); poor specificity (also elevated in skeletal muscle injury); no longer routinely used.
• LDH: Late marker; 24-48 hours; peaks 3-6 days; useful for late presentation.

• Morphine (IV for pain relief; also venodilation reducing preload; analgesic - use cautiously as may impair P2Y12 inhibitor absorption).
• Oxygen: Only if SpO2 <90% (avoid hyperoxia - may increase infarct size).
• Nitrates: Sublingual then IV NTG for pain relief, hypertension, HF; CONTRAINDICATED with PDE5 inhibitors (sildenafil) or RV infarction (causes severe hypotension).
• Aspirin: 325 mg loading dose, chewed immediately (reduces platelet aggregation); then 75-100 mg/day indefinitely.
• Heparin: Anticoagulation (UFH or LMWH); prevents thrombus propagation.
• P2Y12 inhibitors (DAPT - dual antiplatelet therapy): Clopidogrel (loading 300-600 mg), ticagrelor (loading 180 mg - preferred; faster onset, reversible), prasugrel (loading 60 mg - most potent; avoid in prior stroke/TIA, age >75, weight <60 kg).

• Primary PCI (preferred if available): Door-to-balloon time <90 minutes (PCI center) or <120 min (transfer); most effective reperfusion; reduces mortality.
• Fibrinolytic therapy: If primary PCI not available within 120 min; streptokinase, alteplase, tenecteplase; administer within 12 hours of symptom onset (most benefit within 3 hours); contraindicated in: prior hemorrhagic stroke, recent CNS surgery/trauma, active bleeding, aortic dissection.
• CABG: If anatomy not suitable for PCI; mechanical complications (free wall rupture, VSD).

• DAPT: Aspirin + P2Y12 inhibitor for 12 months post-ACS/DES (minimum); lifelong aspirin.
• Statins: High-intensity (atorvastatin 80 mg); reduce LDL <70 mg/dL (ideally <55 mg/dL).
• Beta-blockers: Reduce mortality post-MI; especially with LV dysfunction; continue indefinitely if EF <40%.
• ACE inhibitors/ARBs: Post-MI, EF <40%, HTN, DM, CKD.
• Aldosterone antagonists (eplerenone): EF <40% + symptoms of HF or DM; reduce mortality.
• Cardiac rehabilitation.

---

Q23. Myocardial Infarction and Its Complications

• Myocardial infarction (MI) is irreversible myocardial cell death due to prolonged ischemia (>20-40 minutes of sustained ischemia causes irreversible cell injury).
• Defined by rise and/or fall of cardiac troponin with at least one value above the 99th percentile upper reference limit (URL) AND symptoms, ECG changes, or imaging evidence.

• Ischemia progresses from subendocardium to epicardium over 3-6 hours.
• Subendocardium most vulnerable (farthest from blood supply, highest wall stress).
• Reperfusion within 3-6 hours can salvage significant myocardium.

• Ventricular fibrillation (VF): Most common cause of death post-MI (especially first 24 hours); requires immediate defibrillation; prophylactic lidocaine no longer recommended routinely.
• Ventricular tachycardia (VT): Monomorphic VT in first 48 hours = reperfusion VT (benign); sustained VT/hemodynamically unstable = cardiovert.
• Accelerated idioventricular rhythm (AIVR): 60-100 bpm; sign of reperfusion (benign); no treatment needed.
• Ventricular premature contractions (VPCs): Common; benign; no specific treatment.
• Sinus bradycardia and AV block: Most common in inferior MI (RCA supplies SA and AV nodes); 1st degree AV block, Mobitz I (Wenckebach) = vagal/ischemia; usually resolves; temporary pacing if symptomatic. Complete heart block in inferior MI usually transient. In anterior MI, complete heart block = wide complex escape rhythm, poor prognosis.
• Sinus tachycardia: Most common arrhythmia overall; secondary to pain, anxiety, HF; treat underlying cause.
• Atrial fibrillation: In 10-15% of STEMI; treat with anticoagulation + rate control; worse prognosis.
• Reperfusion arrhythmias: AIVR, VT, bradycardia after reperfusion (normal phenomenon).

• LV dysfunction after large MI → reduced CO → cardiogenic shock (Killip IV).
• Mortality 40-80% without mechanical support.
• Clinical: Hypotension (SBP <90 mmHg), tachycardia, cool extremities, oliguria, altered mental status, pulmonary edema.
• Manage: Inotropes (dobutamine), vasopressors (norepinephrine for refractory shock), IABP (intra-aortic balloon pump), Impella/ECMO (mechanical circulatory support); urgent PCI for culprit lesion.

• Due to papillary muscle dysfunction (ischemia) or rupture (rare but catastrophic).
• Papillary muscle rupture: Days 2-7 post-MI; sudden severe pulmonary edema; new holosystolic murmur; hypotension; cardiogenic shock.
• Posteromedial papillary muscle supplied only by RCA → more vulnerable to infarction than anterolateral PM (dual supply by LAD and LCX).
• Diagnosis: Echocardiography (flail mitral leaflet, severe MR).
• Treatment: Emergency mitral valve surgery; hemodynamic stabilization with IABP, inotropes; IV nitroprusside.

• Due to necrosis of interventricular septum.
• Days 3-7 post-MI; anterior MI → apical VSD; inferior MI → basal VSD.
• Sudden clinical deterioration; new loud holosystolic murmur at LLSB with thrill; right heart failure; step-up in O2 saturation from RA to RV (Swan-Ganz).
• Treatment: Surgical repair or percutaneous closure (after hemodynamic stabilization); temporary IABP; high mortality without surgery.

• Most catastrophic; occurs days 3-7 post-MI (when necrotic wall is softest).
• Causes tamponade → electromechanical dissociation (PEA) → sudden death.
• Risk factors: Elderly, female, first MI, anterior MI, hypertension, no prior angina (no protective ischemic preconditioning), late presentation.
• Incomplete rupture → subacute → pseudoaneurysm (contained rupture by pericardium; risk of delayed rupture; requires urgent surgery).
• True rupture: Sudden tamponade → emergency pericardiocentesis + surgery.

• In 40% of inferior MIs (RCA occlusion proximal to RV branches).
• Clinical triad: Hypotension + Elevated JVP + Clear lungs (key distinguishing features).
• Kussmaul's sign (JVP rises on inspiration).
• ST elevation in right-sided leads (V3R-V4R).
• Management: Aggressive IV fluids (preload dependent); avoid nitrates, diuretics, morphine (reduce preload → worsen hypotension); reperfusion.

• Days 1-3 post-MI; epicardial inflammation → fibrinous pericarditis.
• Pleuritic chest pain; pericardial friction rub.
• Treatment: Aspirin (avoid NSAIDs/steroids - may impair infarct healing).

• Bulging, non-contractile, akinetic or dyskinetic scar after transmural MI (especially anterior MI, LAD territory).
• Incidence: 10-15% of STEMIs.
• Complications: HF, VT (re-entrant circuit), mural thrombus → systemic embolism, pericarditis.
• ECG: Persistent ST elevation in infarct territory (>8 weeks).
• Diagnosis: Echo, cardiac MRI.
• Treatment: Anticoagulation (if thrombus); ICD (if VT); surgery (ventricular reconstruction) if large and symptomatic.

• Incomplete free wall rupture; contained by pericardium and clot.
• Narrow neck (distinguishes from true aneurysm which has wide neck).
• High risk of rupture; urgent surgical repair indicated.

• Forms in areas of akinesis/dyskinesis (especially LV apex in anterior MI).
• Risk of systemic embolism (stroke, limb ischemia, mesenteric ischemia).
• Diagnosis: Echo (bright echogenic mass at apex); cardiac MRI more sensitive.
• Treatment: Anticoagulation (warfarin or NOAC) for 3-6 months (or longer if thrombus persists).

• Autoimmune pericarditis/pleuritis/pneumonitis developing 2-8 weeks (can be months) post-MI.
• Caused by autoantibodies to cardiac antigens released from necrotic myocardium.
• Features: Fever, pleuritic chest pain, pericardial friction rub, pleural effusion, elevated ESR.
• Treatment: Aspirin; NSAIDs; colchicine; steroids (severe/refractory cases).

• Structural changes in non-infarcted myocardium: Compensatory hypertrophy, dilation, change in geometry.
• Adverse remodeling → progressive LV dilation → HF → poor prognosis.
• ACE inhibitors, ARBs, beta-blockers, aldosterone antagonists, ARNI (sacubitril/valsartan) prevent/reverse adverse remodeling.

• Sustained VT/VF: Re-entry circuits around scar; risk of sudden cardiac death.
• ICD implantation: EF <35% despite optimal medical therapy ≥40 days post-MI; primary prevention of SCD.

---

Q24. Conduction System - Normal and Abnormal ECG Patterns (Ventricular and Atrial Arrhythmias, Heart Blocks) and Clinical Manifestations, Diagnosis, etc.

• SA (sinoatrial) node: Primary pacemaker; right atrium near SVC insertion; rate 60-100 bpm; supplied by SA nodal artery (branch of RCA 60%, LCX 40%).
• AV (atrioventricular) node: Right atrium near coronary sinus; slows conduction (critical "delay"); intrinsic rate 40-60 bpm; supplied by AV nodal artery (RCA 90%).
• Bundle of His: Only electrical connection between atria and ventricles; passes through fibrous skeleton; divides into right and left bundle branches.
• Right bundle branch (RBB): Conducts to right ventricle.
• Left bundle branch (LBB): Divides into left anterior fascicle (LAF) and left posterior fascicle (LPF); conducts to left ventricle.
• Purkinje fibers: Final distribution network; intrinsic rate 20-40 bpm; ventricular escape rhythm.
• Normal conduction time: P-R interval 0.12-0.20 sec; QRS ≤0.12 sec; QTc ≤0.44 sec (men), ≤0.46 sec (women).

• P wave: Atrial depolarization; positive in I, II, aVF; upright (sinus); duration <0.12 sec; amplitude <2.5 mm.
• PR interval: 0.12-0.20 sec (3-5 small boxes).
• QRS complex: Ventricular depolarization; duration ≤0.12 sec (3 small boxes); normal axis -30° to +90°.
• ST segment: Isoelectric; ventricular plateau.
• T wave: Ventricular repolarization; upright in I, II, V3-V6; inverted in aVR normally.
• QTc interval: Corrected for HR; Bazett formula: QTc = QT / √RR; Normal: <440 ms (men), <460 ms (women).
• U wave: After T wave; prominent in hypokalemia; represents late repolarization of Purkinje fibers.

• Rate >100 bpm; P before every QRS; regular; gradual onset/offset.
• Causes: Fever, pain, anxiety, anemia, hypovolemia, thyrotoxicosis, HF, PE.
• Treatment: Address underlying cause.

• Rate <60 bpm; P before every QRS; regular.
• Causes: Athletic training, vasovagal, hypothyroidism, hypothermia, inferior MI (vagal tone), beta-blockers, digoxin, CCBs.
• Treatment: If asymptomatic = none; if symptomatic: atropine (acute), pacemaker (chronic).

• Premature P wave of different morphology; followed by narrow QRS (if conducted) or no QRS (blocked PAC).
• Compensatory pause: Incomplete (sinus node reset).
• Usually benign; may trigger SVT/AF if frequent.

• Most common sustained arrhythmia.
• ECG: Irregularly irregular RR intervals; absent P waves; chaotic fibrillatory baseline (350-600 atrial impulses/min); narrow QRS (unless aberrant conduction or WPW).
• Clinical: Palpitations, dyspnea, fatigue; may be asymptomatic; risk of thromboembolic stroke (blood stagnates in LAA).
• CHA2DS2-VASc score (stroke risk): ≥2 in men (≥3 in women) = anticoagulation indicated.
• Causes: Hypertension (most common cause), valvular disease (MS), hyperthyroidism, HF, CAD, alcohol ("holiday heart"), sleep apnea, PE.
• Classification: Paroxysmal (<7 days, self-terminating), Persistent (>7 days, requires cardioversion), Long-standing persistent (>1 year), Permanent (accepted).
• Treatment:
  • Rate control: Beta-blockers, non-DHP CCBs (diltiazem, verapamil), digoxin (if HF).
  • Rhythm control: Cardioversion (electrical or pharmacological), antiarrhythmics (amiodarone, flecainide, propafenone - flecainide ONLY in structurally normal hearts; sotalol).
  • Anticoagulation: Warfarin or NOACs (apixaban preferred; dabigatran, rivaroxaban, edoxaban).
  • Catheter ablation: Pulmonary vein isolation (PVI); for symptomatic paroxysmal/persistent AF.

• Rate: Atrial rate 250-350 bpm (typically 300); ventricular rate depends on AV block (most commonly 2:1 = ventricular rate ~150 bpm).
• ECG: Regular sawtooth baseline (flutter waves) best seen in II, III, aVF; no isoelectric baseline; regular narrow QRS.
• Causes: Similar to AF; COPD, cardiac surgery common.
• Treatment: Rate control; cardioversion (converts at low energy 50 J); catheter ablation (very effective for typical flutter - cavotricuspid isthmus ablation >95% success).
• "If HR is ~150 and regular → think flutter with 2:1 block."

• P waves before QRS but different morphology from sinus P; rate 100-250 bpm.
• Multifocal atrial tachycardia (MAT): ≥3 different P wave morphologies + rate >100; associated with COPD, hypoxia, hypomagnesemia; treatment = treat underlying cause, magnesium.

• AVNRT (AV Nodal Re-entrant Tachycardia): Most common SVT (60%); re-entry within AV node; retrograde P waves buried in or just after QRS ("pseudo R'" in V1, "pseudo S" in inferior leads); regular HR 150-250 bpm; "neck pounding" (cannon a waves).
• AVRT (AV Re-entrant Tachycardia) - orthodromic: Re-entry using accessory pathway (retrograde) and AV node (antegrade); visible retrograde P after QRS in ST segment; associated with WPW.
• Treatment of acute SVT: Vagal maneuvers (Valsalva, carotid sinus massage, cold water face immersion); if unsuccessful → IV adenosine (6 mg then 12 mg; very short half-life ~10 sec; causes transient AV block; contraindicated in WPW with AF, asthma); if unsuccessful → IV diltiazem, verapamil, beta-blockers; DC cardioversion if hemodynamically unstable.
• Long-term: Catheter ablation (>95% success for AVNRT, AVRT).

• Accessory pathway (Bundle of Kent) bypasses AV node → pre-excitation.
• ECG: Short PR (<0.12 sec) + Delta wave (slurred upstroke of QRS) + wide QRS.
• Risk: AF in WPW → accessory pathway conducts very rapidly → very rapid ventricular response → VF → sudden death. CONTRAINDICATION: AV node-blocking drugs (adenosine, diltiazem, verapamil, digoxin) in WPW + AF (increases accessory pathway conduction).
• Treatment: Procainamide or IV flecainide for WPW + AF; catheter ablation of accessory pathway (definitive).

• Wide, bizarre QRS (>0.12 sec) not preceded by P wave; full compensatory pause (SA node not reset).
• Bigeminy (every other beat is PVC); trigeminy (every 3rd); couplets (2 in a row).
• R-on-T phenomenon: PVC falls on T wave → risk of VF (dangerous).
• Causes: Structural heart disease, electrolyte imbalances (hypokalemia, hypomagnesemia), ischemia, caffeine, stimulants, medications.
• Benign if no structural heart disease, asymptomatic, EF normal; PVC >10-15% = risk of PVC-induced cardiomyopathy.
• Treatment: Asymptomatic + structurally normal = reassurance; symptomatic = beta-blockers, CCBs; frequent + cardiomyopathy = ablation.

• ≥3 consecutive ventricular beats at rate >100 bpm; wide QRS (>0.12 sec).
• Sustained VT: ≥30 sec or causing hemodynamic compromise; requires treatment.
• Non-sustained VT (NSVT): <30 sec, self-terminating.
• Monomorphic VT: All QRS identical; typically from scar (post-MI re-entry); more stable hemodynamically.
• Polymorphic VT: Changing QRS morphology; associated with ischemia, LQTS (torsades de pointes = twisting of points around isoelectric line - treat with Mg2+ IV + correct QTc), Brugada.
• Torsades de Pointes: Polymorphic VT in setting of prolonged QT; QRS twists around baseline; triggers: hypokalemia, hypomagnesemia, drugs (antiarrhythmics - sotalol/amiodarone, antibiotics - azithromycin/fluoroquinolones, antipsychotics, antiemetics), congenital LQTS; treatment: IV magnesium sulfate, correct electrolytes, overdrive pacing, remove offending drugs.
• ECG differentiation VT vs SVT with aberrancy: Brugada criteria; AV dissociation = VT (P waves unrelated to QRS); fusion beats = VT; capture beats = VT; extreme axis deviation; negative concordance.
• Treatment: Unstable VT = synchronized cardioversion; stable VT = amiodarone IV; lidocaine (post-MI VT); long-term: ICD; ablation.

• Chaotic, irregular, no recognizable QRS; no effective cardiac output = cardiac arrest.
• Treatment: Immediate defibrillation (unsynchronized); CPR if defibrillator not available; post-ROSC care (targeted temperature management, coronary angiography, treat underlying cause).
• ICD for secondary prevention.

• Autosomal dominant channelopathy (SCN5A mutation - Nav1.5 sodium channel).
• ECG: Type 1 Brugada pattern = coved ST elevation ≥2mm + negative T wave in V1-V3; occurs spontaneously or provoked by fever, sodium channel blockers, vagal tone.
• Risk of VF/SCA; typically in young Asian males; at rest or sleep.
• Diagnosis: Type 1 pattern + clinical criteria (family history SCD, history of syncope, nocturnal agonal breathing).
• Treatment: ICD (only proven therapy); quinidine (reduces VF storm); avoid triggers.

• PR interval >0.20 sec (>200 ms); every P followed by QRS; just prolonged conduction.
• Usually benign; common in athletes, inferior MI (vagal), medications (beta-blockers, digoxin, CCBs).
• No treatment required.

• Mobitz Type I (Wenckebach):
  • Progressive PR lengthening until a P wave is blocked (no QRS follows); then cycle repeats.
  • QRS groups; decreasing RR intervals; RR interval containing dropped beat < 2x preceding RR interval.
  • Site of block: AV node (usually); vagal, inferior MI, digoxin.
  • Usually benign; temporary pacing if symptomatic.
• Mobitz Type II:
  • Constant PR interval; sudden dropped QRS without preceding PR prolongation; QRS often wide (infranodal block).
  • Site: Bundle of His or below; structural disease; anterior MI.
  • Higher risk of complete heart block; pacing indicated even if asymptomatic.

• Complete AV dissociation; P waves and QRS completely independent; ventricular escape rhythm (narrow if junctional 40-60 bpm; wide if ventricular 20-40 bpm).
• Clinical: Bradycardia, syncope (Stokes-Adams attacks), HF, hypotension.
• In inferior MI: Narrow complex, junctional escape, usually transient; temporary pacing.
• In anterior MI: Wide complex, poor prognosis; permanent pacemaker.
• Treatment: Temporary pacing acutely; permanent pacemaker.

• QRS ≥0.12 sec; rSR' ("rabbit ears") in V1; wide S wave in I, V6; T wave inversion V1-V3.
• Can be normal variant; also: ASD, PE (acute cor pulmonale), RV hypertrophy, right heart disease.

• QRS ≥0.12 sec; broad notched R wave (M-shaped) in I, aVL, V5-V6; rS or QS in V1; ST and T changes are secondary (in opposite direction to QRS).
• Always pathological; causes: HTN, CAD, cardiomyopathy, valvular disease.
• New LBBB with chest pain = STEMI equivalent (activate cath lab).
• Discordant ST changes in LBBB normal; concordant changes = Sgarbossa positive (AMI).

• Left anterior fascicular block (LAFB): Left axis deviation (−45° to −90°); qR in I, aVL; rS in II, III, aVF; narrow QRS; no hemodynamic consequence.
• Left posterior fascicular block (LPFB): Right axis deviation (+90° to +180°); qR in II, III, aVF; rS in I, aVL; rare; associated with extensive LV disease.
• Bifascicular block: RBBB + LAFB (most common); or RBBB + LPFB.
• Trifascicular block: Bifascicular + prolonged PR (incomplete) or complete AV block; high risk → pacemaker.

---

Q25. Mitral Valve Disease

• Rheumatic fever (most common cause): Group A streptococcal pharyngitis → molecular mimicry → autoimmune damage; leads to leaflet thickening, commissural fusion, chordal shortening; most patients have concurrent MR.
• Other causes: Congenital (parachute mitral valve), mitral annular calcification (elderly), carcinoid (rare), SLE (Libman-Sacks endocarditis), rheumatoid arthritis.

• Normal MVA (mitral valve area): 4-6 cm².
• Significant MS: MVA <2 cm²; severe: MVA <1 cm²; critical: MVA <0.5 cm².
• Stenosis → elevated LA pressure → LA dilation → pulmonary venous hypertension → pulmonary arterial hypertension → RV hypertrophy/failure.
• LA dilation → atrial fibrillation → loss of atrial kick (worsens symptoms) + thrombus in LAA → embolic stroke.

• Malar flush (pink-purple cheeks; mitral facies): Low CO + peripheral vasoconstriction.
• Tapping apex beat (palpable S1 due to thickened leaflets snapping shut at low LV pressure).
• Left parasternal heave (RV hypertrophy from pulmonary HTN).
• Palpable P2 (pulmonary HTN).
• Loud S1 (thickened but pliable leaflets; disappears when calcified and immobile).
• Opening Snap (OS): High-pitched; early diastole; shorter S2-OS interval = more severe stenosis (higher LA pressure).
• Mid-diastolic rumbling murmur at apex: Low-pitched; best heard with bell in left lateral decubitus; increases after exercise or with maneuvers that increase flow.
• Presystolic accentuation: Crescendo murmur immediately before S1 (atrial systole squeezing blood through tight valve); absent in AF.
• Graham-Steell murmur (early diastolic murmur at LLSB): Pulmonary regurgitation from pulmonary HTN.

• Medical: Diuretics (relieve congestion); beta-blockers/CCBs (rate control + prolong diastolic filling); anticoagulation (AF, prior embolism, MVA <1.5 cm²).
• Percutaneous balloon mitral valvotomy (PBMV/BMV): Procedure of choice for severe MS (MVA <1.5 cm²) with favorable anatomy (Wilkins score ≤8); done via transseptal puncture; balloon inflated across mitral valve; excellent results.
• Surgical mitral valve repair or replacement: Unfavorable anatomy, concomitant MR, thrombus in LAA.

---

• Acute MR: Papillary muscle rupture (post-MI), chordae tendineae rupture (IE, MVP, trauma), leaflet perforation (IE).
• Chronic MR:
  • Mitral valve prolapse (most common cause in developed countries).
  • Rheumatic disease.
  • Mitral annular dilation (dilated cardiomyopathy, ischemic heart disease).
  • Infective endocarditis.
  • Congenital (cleft mitral valve in AV canal defect).
  • Connective tissue disease (Marfan, Ehlers-Danlos).

• Most common valvular abnormality; 2-3% of population; more common in tall, thin young women.
• Myxomatous degeneration of leaflets → leaflet billowing into LA during systole.
• Mid-systolic click (hallmark) ± late systolic murmur of MR.
• Complications: MR, IE, sudden death (rare, associated with bileaflet prolapse + severe MR), arrhythmias, emboli.

• Regurgitant fraction returns to LA → LA dilation → elevated LA pressure (if compensation lost).
• LV compensates initially: Eccentric hypertrophy (dilation); preserved EF initially.
• Eventually: Afterload increases → LV dysfunction; EF may be falsely normal (regurgitant volume contributes to ejection); EF <60% in MR = LV dysfunction.

• Holosystolic (pansystolic) murmur: Harsh or blowing; at apex; radiates to axilla (posterior leaflet MR); or to base (anterior leaflet MR); loudest with expiration; increases with handgrip and squatting (increased afterload); decreases with Valsalva.
• Hyperdynamic, displaced apex (LV volume overload).
• S3 gallop (volume overload).
• Soft S1 (incomplete valve closure).
• Wide splitting of S2 (early aortic valve closure due to reduced forward stroke volume).

• Acute severe MR: Emergency surgery; hemodynamic stabilization with IABP, nitroprusside (reduce afterload).
• Chronic MR: Watchful waiting until symptoms or LV dysfunction (EF <60% or LVESD >40 mm).
• Surgery: Mitral valve repair (preferred over replacement; preserves chordal apparatus); repair for degenerative (MVP) MR; replacement for complex rheumatic MR.
• MitraClip (transcatheter edge-to-edge repair/TEER): For high surgical risk patients; clips anterior and posterior leaflets together (double-orifice repair).

---

Q26. Aortic Valve Disease

• Calcific (degenerative) AS: Most common cause in adults >65; calcium deposition on leaflets; 3-cusp valve; progressive.
• Bicuspid aortic valve (BAV): Most common congenital heart defect; develops severe AS earlier (40-50 years); also associated with aortic root dilation, coarctation.
• Rheumatic AS: Commissural fusion; almost always with rheumatic MV disease; developing countries.
• Congenital valvular AS (unicuspid/bicuspid): Children/young adults.
• Subvalvular AS (HOCM): Dynamic outflow obstruction.
• Supravalvular AS: Williams syndrome.

• Mild: Valve area >1.5 cm²; mean gradient <25 mmHg.
• Moderate: Area 1.0-1.5 cm²; mean gradient 25-40 mmHg.
• Severe: Area <1.0 cm²; mean gradient ≥40 mmHg; peak velocity ≥4 m/s.
• Very severe: Area <0.6 cm²; mean gradient ≥60 mmHg.
• Normal aortic valve area: 3-4 cm².

• Syncope: Due to fixed CO; inability to increase flow with exertion; vasodilation not matched by increased CO; average survival 3-5 years.
• Angina: RV-equivalent ischemia of hypertrophied LV (subendocardial ischemia); average survival 5 years.
• Dyspnea (HF): LV diastolic/systolic failure; average survival 1-2 years without valve replacement.

• Fixed outflow obstruction → LV pressure overload → concentric LVH (pressure overload → wall stress = P×r/2h; increased thickness reduces wall stress) → diastolic dysfunction → eventually systolic dysfunction → heart failure.
• Calculated gradient increases as severity worsens; in severe LV dysfunction ("low-flow, low-gradient AS"), mean gradient may be misleadingly low despite critical stenosis.

• Pulse: Pulsus parvus et tardus (small amplitude, slow-rising, delayed carotid pulse); sustained carotid upstroke with a notch (anacrotic notch).
• Apical impulse: Sustained, heaving, non-displaced (concentric LVH without dilation).
• Systolic thrill at 2nd right ICS (if severe, grade IV).
• Ejection click (in bicuspid/mobile valve; absent in calcified immobile valve).
• S4 gallop (stiff, hypertrophied LV).
• Murmur: Harsh, crescendo-decrescendo (ejection) systolic murmur; best heard at 2nd right ICS; radiates to carotids; Gallavardin phenomenon: murmur transmits to apex in high-pitched musical quality (may mimic MR - but apical component is musical, not blowing, and radiates differently).
• Soft or absent A2: Calcified, immobile valve.

• Echocardiography: Valve area (planimetry, continuity equation), mean/peak gradient, peak velocity, LVH, EF.
• Cardiac catheterization: "Low-flow low-gradient AS" - dobutamine stress echo or cath for gradient measurement.
• CT calcium scoring: Aortic valve calcium score >3000 AU (men), >1600 AU (women) = severe AS with high certainty.

• No effective medical therapy to slow progression.
• Aortic Valve Replacement (AVR): Only effective treatment; indicated when severe AS + any symptom (syncope, angina, dyspnea) OR asymptomatic severe AS with EF <50% OR severe AS + another cardiac surgery.
• TAVR (Transcatheter Aortic Valve Replacement): Catheter-based; valve-in-valve; now approved for low, intermediate, and high surgical risk; access: transfemoral (preferred), transapical, transaortic.
• SAVR (Surgical AVR): For patients requiring concomitant cardiac surgery, bicuspid valve with aortopathy, low surgical risk young patients.
• Post-AVR: Annual follow-up echo; anticoagulation for mechanical prosthesis; DAPT for TAVR (aspirin + clopidogrel for 3-6 months then aspirin alone).

---

• Acute AR: Aortic dissection (Type A involving aortic root), infective endocarditis (leaflet destruction/perforation), trauma.
• Chronic AR:
  • Valve abnormality: Rheumatic fever, bicuspid aortic valve, IE (chronic), degenerative.
  • Aortic root dilation: Marfan syndrome, ankylosing spondylitis, syphilitic aortitis, hypertension (causes aortic root dilation), idiopathic root dilation.

• Regurgitant fraction fills LV from aorta during diastole → LV volume overload → eccentric LVH (dilation) → increased stroke volume → wide pulse pressure → characteristic peripheral signs.
• Aortic diastolic pressure falls (regurgitation) → wide pulse pressure.
• LV adapts with dilation for years; eventually wall stress increases → LV dysfunction.

• Acute severe AR: Sudden catastrophic pulmonary edema, cardiogenic shock; requires emergency surgery; LV cannot dilate rapidly enough to accommodate large regurgitant volume.
• Chronic: Asymptomatic for years; dyspnea (earliest symptom), orthopnea, palpitations, "pounding" sensation in chest (due to large stroke volume), exertional angina, head bobbing.

• Water-hammer (Corrigan's) pulse: Abrupt forceful rise, rapid collapse; best felt by raising arm above head level.
• Wide pulse pressure: SBP elevated (large stroke volume), DBP low (diastolic runoff into LV); e.g., 170/40 mmHg.
• Hill's sign: Popliteal SBP > brachial SBP by >20 mmHg (>60 mmHg = severe).
• De Musset's sign: Head bobbing with each heartbeat.
• Quincke's pulsations: Visible capillary pulsations in nail beds on gentle pressure.
• Duroziez's sign: To-and-fro murmur over femoral artery with slight compression of stethoscope.
• Traube's sign ("pistol shot"): Loud systolic/diastolic sound over femoral artery.
• Müller's sign: Visible pulsations of uvula.
• Landolfi's sign: Alternating pupil constriction and dilation.
• Apex: Displaced, hyperdynamic (volume overload); "dancing heart."
• Murmur: High-pitched, blowing, decrescendo early diastolic murmur at LLSB (3rd-4th ICS); best with patient sitting forward, in expiration; increases with handgrip; softer in sitting and lying.
• Austin Flint murmur: Mid-diastolic rumble at apex (regurgitant jet hits anterior MV leaflet causing functional mitral stenosis); distinguished from MS: no OS; both have AR murmur.
• S3 (volume overload).

• Acute severe AR: Emergency surgery.
• Chronic AR: Serial echo monitoring (annual if mild-mod; every 6-12 mo if severe).
• AVR indicated: Severe AR + symptoms; or severe AR + LV dilation (LVESD >50 mm or LVEDD >65 mm); or EF <50%.
• Vasodilators (nifedipine, ACE inhibitors): In chronic AR to reduce afterload; only use if surgery not yet indicated (no proven mortality benefit).

---

Q27. Tricuspid Valve Disease

• Rheumatic fever: Most common cause; almost always associated with mitral and/or aortic valve disease; isolated TS is rare.
• Carcinoid syndrome: Carcinoid tumors of small bowel → serotonin/5-HIAA → tricuspid and pulmonary valve fibrosis and retraction; right-sided valves affected (not left, as serotonin is inactivated by lung).
• Right atrial tumors (myxoma).
• Congenital (rare).
• Infective endocarditis (IV drug users).

• Normal TV area: 7-9 cm²; TS significant when <1.5 cm².
• Obstruction → elevated RA pressure → systemic venous hypertension → JVD, hepatomegaly, ascites, peripheral edema (without pulmonary edema - left heart unaffected).
• Reduced CO → fatigue, weakness.
• Pressure gradient across TV: Mean gradient >5 mmHg = significant TS.

• Fatigue, weakness (reduced forward CO).
• Peripheral edema, abdominal distension (ascites), jaundice (hepatic congestion).
• Often masked by coexisting MS symptoms (MS usually dominates clinically).

• Elevated JVP with prominent a wave (giant a wave: atrial systole against closed stenotic valve).
• Slow y descent (slow RA emptying in diastole).
• Hepatomegaly (presystolic pulsation before tricuspid opens in sinus rhythm).
• Ascites, peripheral edema.
• Murmur: Low-pitched, diastolic, rumbling murmur at left lower sternal border (4th ICS) and xiphoid; distinguished from MS by:
  • Increases with inspiration (right-sided - Carvallo's sign); MS does not change reliably with respiration.
  • Location (left lower sternal border vs. apex for MS).
  • Opening snap of TS heard at LLSB, not apex.

• Echocardiography: Thickened, restricted TV leaflets; Doppler gradient; planimetry of TV area; RA/IVC dilation.
• Cardiac catheterization: RA-RV diastolic pressure gradient.

• Medical: Diuretics for symptomatic relief; sodium restriction.
• Surgical: TV repair or replacement (bioprosthesis preferred over mechanical for TV); usually done simultaneously with mitral valve surgery; balloon valvuloplasty less successful than for MS due to more severe leaflet deformity.

---

• Functional (secondary) TR: Most common type (75%); not primary TV disease; RV dilation (from any cause of pulmonary hypertension or RV failure) → annular dilation → leaflet malcoaptation.
  • Causes: LV failure → pulmonary HTN → RV failure → TR; mitral valve disease, COPD, PE, Eisenmenger syndrome.
• Primary (organic) TR:
  • Rheumatic disease.
  • Infective endocarditis (IE): IV drug users; right-sided IE; Staphylococcus aureus most common.
  • Carcinoid syndrome.
  • Myxomatous degeneration (TR prolapse).
  • Trauma, radiation, iatrogenic (pacemaker leads).
  • Ebstein anomaly (downward displacement of TV into RV; right-sided HF + arrhythmias + cyanosis).
  • Rheumatoid arthritis.

• Peripheral edema, ascites, hepatic congestion (right-sided overload).
• Fatigue, weakness.
• Pulsatile liver.
• Pulsatile hepatomegaly.

• Elevated JVP with giant cv waves (systolic filling of jugular veins from regurgitation).
• Prominent v wave + rapid y descent in JVP.
• Hepatic pulsation (systolic hepatic pulsation).
• Murmur: Holosystolic, blowing murmur at left lower sternal border/xiphoid; increases with inspiration (Carvallo's sign / Rivero-Carvallo sign); may be inaudible in severe TR with equalization of pressures.
• Right ventricular S3 (right-sided HF).
• Parasternal heave (RV enlargement).
• Pulsatile jugular venous waveform visible.

• Echocardiography: Visualize TR jet (color Doppler); estimate RVSP; RV dilation/function; RA dilation; IVC plethora (IVC >2.1 cm + <50% collapse = elevated RA pressure >10 mmHg).

• Functional TR: Treat underlying cause (diuretics, afterload reduction for LV failure; pulmonary vasodilators).
• Surgical TV repair: At the time of left-sided valve surgery if TR is moderate-severe or annulus is dilated.
• TV annuloplasty (ring repair): Preferred over replacement.
• TV replacement: If severe organic TR or failed repair (bioprosthetic preferred; mechanical thrombosis risk higher in TV than other positions).
• Isolated TV surgery: Only if severe symptomatic TR despite medical therapy.
• Transcatheter TV interventions (TRILUMINATE, CLASP, etc.): Emerging; for high surgical risk patients.

---

Q28. Athlete's Heart and Sudden Cardiac Death in Athletes

• Athlete's heart (also called athletic heart syndrome) refers to the physiological structural and functional adaptations of the heart in response to sustained intense endurance or strength training; a normal, benign condition.
• Distinguished from pathological hypertrophy (cardiomyopathy).

• LV dilation (increased LVEDV): Increased preload during intense exercise → increased EDV (Frank-Starling mechanism); LV cavity enlargement.
• LV wall hypertrophy: Increased LV mass; increased wall thickness (12-13 mm in extreme cases); but increased proportionally with cavity (eccentric pattern in endurance athletes; concentric in power athletes).
• Increased cardiac mass: Up to 45% greater than sedentary controls.
• RV dilation: Parallel dilation of RV.
• LA dilation: Due to increased venous return.
• Type of remodeling by sport:
  • Endurance sports (marathon, cycling, triathlon): High sustained cardiac output demand → eccentric LVH (dilation + mild thickening).
  • Strength/power sports (weightlifting, wrestling): High pressure demand → concentric LVH (thickening without dilation).
  • Combined (rowing, swimming): Combination of both.

• Resting bradycardia: HR 30-60 bpm at rest; due to increased vagal tone and intrinsic SA node remodeling; sinus bradycardia in athletes is normal.
• Increased stroke volume (SV): Larger SV compensates for lower HR to maintain CO.
• Increased VO2 max (maximum oxygen uptake): Best measure of cardiorespiratory fitness; highly trained athletes: VO2 max 60-80+ mL/kg/min (normal adults: 30-45 mL/kg/min).
• Improved cardiac efficiency: Better coronary flow, better myocardial oxygen utilization.
• Diastolic function preserved or improved: Normal E/A ratio (often elevated, supranormal relaxation).

• Sinus bradycardia (<60 bpm).
• Sinus arrhythmia.
• First-degree AV block (prolonged PR).
• Mobitz I (Wenckebach) second-degree AV block.
• Incomplete RBBB.
• Early repolarization (ST elevation with J-point elevation, "fishhook" or "notch" at J point in V3-V5): Normal in athletes.
• Increased QRS voltage (LVH voltage criteria met without true pathological LVH).
• T-wave inversion in aVR: Normal.
• Junctional/nodal rhythm.

• T-wave inversions: V2 onwards (except V1); lateral leads (V5-V6); inferolateral (II, III, aVF, V4-V6).
• ST segment depression.
• Pathological Q waves.
• Complete LBBB or RBBB.
• Long QT (QTc >470 ms men, >480 ms women).
• Short QT (QTc <320 ms).
• Brugada pattern.
• Ventricular pre-excitation (delta waves).
• Non-sinus rhythm (other than sinus bradycardia).
• Frequent ventricular ectopy.

---

• Sudden cardiac death is unexpected death from a cardiac cause within 1 hour of symptom onset (or unwitnessed death within 24 hours of last being seen alive).
• In athletes: Occurs during or shortly after vigorous exercise; particularly tragic due to young age and apparent health.

• Incidence: ~1:50,000 to 1:80,000 per year in young athletes (age <35).
• Young male athletes (particularly basketball and football players in the US; African-Caribbean athletes at higher risk for HCM-related SCD) have higher incidence.
• Male > Female (10:1).
• More common in competitive than recreational athletes.
• African Americans: Higher proportion of HCM-related SCD.

1. Hypertrophic Cardiomyopathy (HCM): Most common cause of SCD in athletes in the United States (~40%); autosomal dominant; sarcomere mutations; asymmetric septal hypertrophy; LVOT obstruction; arrhythmias; diagnosed by echo (septal thickness ≥15 mm, or ≥13 mm with family history); systolic anterior motion (SAM) of anterior MV leaflet; cavitary obliteration.
2. Commotio Cordis: Second most common cause; SCD from blunt, non-penetrating, low-energy blow to the chest wall during the vulnerable period of ventricular repolarization (15-30 ms before T-wave peak) → VF; no structural heart disease; most common in young males during sports (baseball, hockey puck, softball); survival improved with immediate defibrillation.
3. Congenital Coronary Artery Anomalies: Anomalous origin of left coronary artery (LCA) from right sinus of Valsalva → acute angle take-off → compression between aorta and pulmonary trunk during exercise → ischemia → VF. Third most common cause in some series.
4. Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC/ARVD): Most common cause in Italy (Veneto region); autosomal dominant; desmosomal gene mutations (PKP2 most common); RV myocardium replaced by fibrofatty tissue → RV dilation → VT/VF; "epsilon wave" (small deflection after QRS in V1-V3), late potentials, T-wave inversions V1-V3; triggered by exercise.
5. Coronary Artery Disease: In older athletes (>35 years); most common cause in athletes >35.
6. Myocarditis: Viral (Coxsackievirus B most common); inflammation → arrhythmias; typically after viral illness; biomarkers elevated; cardiac MRI diagnostic.
7. Dilated Cardiomyopathy.
8. Valvular disease: Aortic stenosis; MVP with severe MR.
9. Aortic rupture/dissection: Marfan syndrome; bicuspid aortic valve with aortic root dilation.

• Purpose: Identify athletes at risk before SCD occurs; requires balance of sensitivity vs. specificity; avoid over-diagnosis causing unnecessary disqualification.
• US Approach (AHA 14-element history and physical examination):
  • Detailed personal/family history + physical examination; ECG NOT routinely recommended (high false-positive rate in US due to diverse athletic populations, costs, and insufficient cardiologist availability).
  • History: Exertional chest pain, unexplained syncope, excessive dyspnea with exertion, family history of SCD <50 years, known cardiac diagnosis.
  • Physical: Heart murmur (sitting and standing), brachial artery BP, stigmata of Marfan syndrome, femoral pulses (coarctation).
• European Approach (European Society of Cardiology): 12-lead ECG included in routine screening; more sensitive but more false positives; refined ECG criteria (Seattle Criteria, International Criteria) reduce false positives.
• If screening is abnormal: Referral for echocardiography, exercise stress test, Holter, cardiac MRI, genetic testing.
• Eligibility: Based on 36th Bethesda Conference Guidelines and ESC recommendations; some conditions disqualify from competitive sports (HCM with high-risk features, ARVC, severe AS, symptomatic WPW, etc.); shared decision-making approach increasingly advocated (AHA/ACC 2015).

• All athletic venues should have AEDs (automated external defibrillators) and trained personnel.
• Immediate CPR + defibrillation (within 3-5 minutes) → survival >90%.
• Each 1-minute delay in defibrillation → 10% decrease in survival.
• Emergency Action Plan (EAP) mandatory at sports facilities.

• HCM: Beta-blockers for symptoms; ICD if high-risk (NSVT, family history SCD, syncope, massive LVH ≥30 mm, abnormal BP response to exercise); surgical myectomy/alcohol septal ablation for refractory LVOTO; sports restriction (no competitive sports in most guidelines, though recent data suggest lower risk than previously thought).
• ARVC: ICD; avoid all competitive sports (exercise accelerates disease progression); catheter ablation for VT.
• LQTS: Beta-blockers (especially LQT1 and LQT2); ICD (secondary prevention or high-risk primary prevention); avoid QT-prolonging drugs; competitive sport disqualification.
• CPVT: Beta-blockers; flecainide (adjunct); ICD; avoid exercise in high-risk.
• Anomalous coronary arteries: Surgical reimplantation/unroofing of anomalous coronary.
• Myocarditis: No competitive sports for at least 3-6 months; until full recovery, biomarkers normal, normal LV function on echo/CMR, no arrhythmias.

---

CADM - Cardiovascular System: Q21 to Q30

Reference: Bates' Guide to Physical Examination and History Taking, Lynn S. Bickley, 13th Edition, 2023

---

Q21. Fibromuscular Dysplasia - Including Clinical Manifestations, Diagnosis, Complications, etc.

• Fibromuscular dysplasia (FMD) is a non-inflammatory, non-atherosclerotic, segmental disease of medium-sized arteries affecting primarily the arterial wall media and, less commonly, the intima or adventitia.
• It causes stenosis, aneurysm, dissection, and occlusion of affected arteries.
• Predominantly affects young to middle-aged women (90% of cases).

• Prevalence: ~4% in women undergoing abdominal aortic aneurysm screening (incidental finding).
• Female predominance: >90%.
• Peak presentation: 40-60 years of age.
• Increasingly recognized as underdiagnosed.
• Most common in Caucasian women; rare in Asian and African populations.

• Exact cause unknown; multifactorial.
• Proposed mechanisms:
  • Hormonal factors: Estrogen stimulates arterial smooth muscle proliferation (explains female predominance and worsening during pregnancy).
  • Mechanical stress: Repetitive stretching of arterial wall from hemodynamic forces.
  • Genetic predisposition: ~7-11% familial; ARCN1 and other genes implicated; autosomal dominant with variable penetrance.
  • Arterial wall ischemia: Abnormal vasa vasorum supply to arterial wall.
  • Smoking: Major modifiable risk factor; associated with arterial dissection in FMD.
  • Oral contraceptive use: Possibly promotes disease activity.
• Pathology: Smooth muscle cell proliferation and disorganization + fibrous tissue deposition in media → alternating segments of stenosis and dilation → classic "string of beads" appearance.
• Not related to atherosclerosis (different risk factors, different demographics, different pathology - no lipid deposition, no inflammation).

1. Renal arteries (60-75%): Most common site; often bilateral; mid and distal segments preferentially (distinguishes from atherosclerosis which affects ostia/proximal).
2. Cervicocephalic arteries (25-30%): Internal carotid and vertebral arteries; mid-cervical ICA most common; also intracranial vessels.
3. Mesenteric/celiac arteries: Less common.
4. Iliac arteries: Less common; lower limb claudication.
5. Coronary arteries: Rare; associated with spontaneous coronary artery dissection (SCAD).
6. Multi-vessel involvement: In up to 65% of patients; therefore all vascular beds should be screened when FMD diagnosed in one territory.

• Renovascular hypertension: Most common presentation; young woman with difficult-to-control hypertension; hypertension onset often before age 35.
• Abdominal/flank bruit: High-pitched systolic-diastolic bruit in the upper abdomen/flanks.
• Renal infarction (from in-situ thrombosis or emboli from dissection).
• Renal artery aneurysm → risk of rupture (rare but life-threatening, especially during pregnancy).
• Hematuria.
• Acute or chronic renal failure (bilateral severe FMD).
• Worsening renal function with ACE inhibitor/ARB (similar to atherosclerotic renal artery stenosis).

• Pulsatile tinnitus (most common presenting symptom of cervical FMD): Whooshing or ringing sound in ear; due to turbulent flow in ICA near ear.
• Headache: Chronic, often unilateral; migrainous quality.
• TIA/ischemic stroke: Thromboembolism from stenosis/aneurysm; arterial dissection causing thromboembolism.
• Cervical arterial dissection (carotid or vertebral): Most serious complication; presents as sudden severe head/neck pain (thunderclap headache), Horner syndrome (ptosis, miosis, anhidrosis - from ICA dissection compressing cervical sympathetics), TIA, stroke.
• Neck pain: Spontaneous cervical artery dissection.
• Subarachnoid hemorrhage: Rupture of intracranial FMD-related aneurysm.
• Carotid bruit.
• Dizziness, visual disturbances (vertebrobasilar FMD).

• Chronic mesenteric ischemia: Postprandial angina, weight loss, food fear.
• Intestinal infarction (rare).

• Spontaneous coronary artery dissection (SCAD): Acute MI in young women; often peripartum.

• Fatigue, connective tissue laxity.
• Overlap with connective tissue disorders: Ehlers-Danlos syndrome type IV (vascular), Marfan syndrome.
• Associated with intracranial aneurysms (in 7-10% of cervicocephalic FMD) → screening warranted.

• CT Angiography (CTA): First-line non-invasive imaging; high resolution; detects "string of beads," stenosis, aneurysms, dissections; covers multiple vascular territories simultaneously; limitation: radiation, contrast.
• MR Angiography (MRA): Excellent for cervicocephalic FMD; no radiation; may miss small lesions; gadolinium contrast required; preferred for pregnant patients.
• Duplex Doppler Ultrasound: Renal artery Doppler (peak systolic velocity >180 cm/s = stenosis); useful for follow-up; limited by body habitus and operator skill; cannot image intracranial vessels.
• Digital Subtraction Angiography (DSA): Gold standard; most detailed visualization; allows simultaneous therapeutic intervention (angioplasty); demonstrates "string of beads" most clearly; shows small lesions not seen on CTA/MRA; invasive.
• Characteristic "string of beads": Multiple alternating zones of stenosis and dilation; beads larger than normal vessel lumen (distinguishes medial FMD from intimal FMD).

• No specific biomarkers for FMD.
• Renal function tests (creatinine, GFR).
• Urine analysis (proteinuria, hematuria).
• Plasma renin activity and aldosterone (elevated in renovascular HTN from FMD).
• CBC, ESR, CRP (to exclude vasculitis: ESR elevated in vasculitis but normal in FMD - important distinction).
• ANA, ANCA (to exclude autoimmune vasculitis).

• Arterial dissection: Spontaneous tearing of arterial wall; most feared acute complication; carotid and vertebral dissection → stroke; renal dissection → infarction; coronary dissection (SCAD) → MI.
• Arterial aneurysm and rupture: Renal artery aneurysm (rupture risk especially in pregnancy); intracranial aneurysm → subarachnoid hemorrhage.
• Stroke and TIA: Thromboembolism from stenosis, aneurysm, or dissection in cervical FMD.
• Renovascular hypertension: End-organ damage (LVH, CKD, retinopathy) if uncontrolled.
• Renal failure: Bilateral severe renal FMD.
• Bowel infarction: Mesenteric FMD occlusion.
• Horner syndrome: ICA dissection.
• Pregnancy complications: Worsening of FMD; renal artery aneurysm rupture; SCAD peripartum; preeclampsia from renovascular HTN.

• Antiplatelet therapy (aspirin 100 mg/day): Recommended for all symptomatic cervicocephalic FMD and after cervical artery dissection; reduces thromboembolic risk.
• Anticoagulation: For acute cervical artery dissection with stroke/TIA: Heparin then warfarin or NOAC for 3-6 months (debated vs. antiplatelet).
• Antihypertensive therapy: ACE inhibitors/ARBs (caution: may worsen renal function in bilateral RAS; use with close monitoring); beta-blockers, CCBs for BP control.
• Smoking cessation: Strongly recommended (major modifiable risk factor for dissection).
• Avoid oral contraceptives (especially with cervicocephalic FMD).

• Percutaneous Transluminal Angioplasty (PTA): Treatment of choice for symptomatic renal FMD causing renovascular hypertension; success rate >80-90%; balloon angioplasty alone (without stenting in most cases); stenting reserved for failed angioplasty, dissection, or restenosis; superior to medical therapy alone for BP control in renal FMD.
• Carotid/vertebral PTA: For symptomatic cervicocephalic FMD with hemodynamically significant stenosis.
• Stent placement: For FMD with focal dissection or failed angioplasty.
• Surgical repair: For complex disease (long-segment stenosis, aneurysm requiring repair, failed PTA); ex-vivo renal arterial reconstruction; bypass grafting.
• Intracranial aneurysm treatment: Coiling (endovascular) or clipping (surgical) based on size and morphology.

• Annual imaging surveillance (CTA or MRA) for known FMD.
• Screen all vascular territories (renal, cervicocephalic, visceral) when FMD diagnosed.
• Screen for intracranial aneurysms (CTA/MRA head) in all cervicocephalic FMD patients.
• Patient registry and education (United States Registry for FMD - USRFMD).

---

Q22. Peripheral Arterial Aneurysms and Its Complications

• A peripheral arterial aneurysm is a localized, permanent, abnormal dilation of a peripheral artery to >1.5 times its normal diameter (or >50% dilation above normal diameter).
• True aneurysm: All three vessel wall layers (intima, media, adventitia) involved.
• False (pseudo) aneurysm: Only adventitia (or surrounding tissue) containing the hematoma; no true wall layers.
• Fusiform: Symmetric, spindle-shaped dilation of entire circumference.
• Saccular: Asymmetric, outpouching of one side; higher risk of rupture and thrombosis.

• Most common peripheral artery aneurysm (70% of all peripheral aneurysms).
• Normal popliteal artery diameter: ~1 cm; aneurysm if ≥2 cm.
• Bilateral in 50-70%; associated with abdominal aortic aneurysm (50% of patients with PAA have AAA; therefore AAA screening mandatory).
• Demographics: Predominantly older men (>60 years); rare in women.
• Etiology: Atherosclerosis (most common); connective tissue disorders; trauma.
• Complications (serious; most are asymptomatic until complication):
  • Thromboembolism (most common complication): Distal embolization → acute limb ischemia ("blue toe syndrome," acute occlusion of tibial arteries) → most feared complication.
  • Thrombosis of aneurysm sac → acute limb ischemia.
  • Popliteal vein compression → DVT; leg edema.
  • Tibial nerve compression → pain, paresthesia in foot.
  • Rupture (rare: only 2-5%; unlike AAA, PAA rarely ruptures).
  • Chronic limb ischemia: Distal occlusion from repeated emboli.
• Clinical: Often asymptomatic until thromboembolism; popliteal mass (pulsatile) behind knee; intermittent claudication; cold foot; blue or white toes.
• Diagnosis: Duplex ultrasound (first-line; confirms aneurysm, size, thrombus, patency); CT angiography (planning for surgery); MR angiography.
• Treatment: Elective surgery recommended for symptomatic PAA OR asymptomatic if ≥2 cm or significant thrombus (to prevent thromboembolism before it occurs); vein bypass grafting (saphenous vein preferred); endovascular exclusion with covered stent-graft; ligation and bypass.

• Second most common peripheral aneurysm.
• True femoral aneurysm: Atherosclerotic; bilateral in 72%; associated with PAA and AAA.
• Pseudoaneurysm: More common than true; causes: iatrogenic (post-cardiac catheterization from femoral access - most common); trauma; infection (mycotic); IV drug use.
• Normal common femoral artery: ~1 cm; aneurysm if ≥2.5 cm.
• Complications: Distal embolism, thrombosis, compression of femoral vein (edema, DVT) or femoral nerve (thigh pain, quadriceps weakness), rupture (pseudoaneurysms), infection.
• Post-catheterization pseudoaneurysm:
  • Complication of femoral arterial access (cardiac catheterization, PCI, angiography).
  • Pulsatile groin mass + systolic bruit after procedure.
  • Diagnosis: Duplex ultrasound (classic finding: swirling flow "yin-yang sign" in color Doppler + to-and-fro signal in neck of pseudoaneurysm).
  • Treatment: Ultrasound-guided thrombin injection (most effective, >95% success); ultrasound-guided compression; surgical repair (large >3 cm, expanding, failed thrombin).
• True femoral aneurysm treatment: Surgical repair when symptomatic or ≥2.5 cm; endovascular excluded.

• Rare; associated with thoracic outlet syndrome (TOS), post-stenotic dilation.
• Complications: Distal upper limb embolism (most common), axillary vein compression, rupture.
• Diagnosis: Duplex US, CTA.
• Treatment: Surgical; must address underlying TOS (first rib resection) + aneurysm repair.

• Splenic artery aneurysm: Most common visceral aneurysm (60%); female predominance; associated with portal hypertension, multiple pregnancies, FMD; risk of rupture especially in pregnancy (maternal mortality up to 75% if rupture during pregnancy).
  • Treatment: If symptomatic, expanding, in women of childbearing age, or ≥2 cm → endovascular (coiling/stenting) or surgical.
• Celiac, hepatic, superior mesenteric aneurysms: Less common; atherosclerotic or FMD.
• Hepatic artery aneurysm: Risk of rupture into biliary tree (hemobilia) or peritoneum.

• True carotid aneurysm: Very rare; atherosclerosis, trauma, FMD.
• Internal carotid artery pseudoaneurysm: Trauma, infection (mycotic), post-endarterectomy.
• Complications: TIA, stroke (thromboembolism), cranial nerve compression, rupture.
• Treatment: Surgical or endovascular (covered stent).

• Associated with FMD (most common cause), atherosclerosis.
• Predominantly affects women.
• Complications: Rupture (especially in pregnancy), thromboembolism → renal infarction, renovascular hypertension, hematuria.
• Treatment: Surgical or endovascular repair if symptomatic, ≥2 cm, or in woman of childbearing age.

• Distal embolism: Most serious functional complication; platelet/thrombus microemboli from aneurysm sac → digital ischemia, blue toe syndrome, acute tibial artery occlusion.
• Thrombosis of aneurysm: Acute limb ischemia; requires emergency revascularization.
• Compression of adjacent structures: Vein (edema/DVT), nerve (pain/paresthesia), airway (thoracic), ureter.
• Rupture: Less common in peripheral than aortic aneurysms (except in visceral); life-threatening.
• Infection (mycotic aneurysm): Septic emboli, life-threatening; aggressive IV antibiotics + urgent surgery.
• Fistula formation: Arteriovenous fistula.

• Duplex Doppler Ultrasound: First-line; non-invasive; confirms diagnosis, size, thrombus, velocity; use for surveillance.
• CT Angiography: Definitive preoperative planning; shows 3D anatomy, extent, relationship to adjacent structures.
• MR Angiography: Alternative to CTA; no radiation; good soft tissue detail.
• Digital Subtraction Angiography (DSA): Invasive; used pre-operatively or during endovascular intervention; best for runoff vessel assessment.
• When PAA diagnosed: Screen for contralateral PAA + screen for AAA (bilateral renal-to-femoral CTA).

---

Q23. Raynaud's Syndrome

• Raynaud's phenomenon (RP) is episodic, reversible vasospasm of digital (finger and toe) arteries and arterioles in response to cold exposure or emotional stress, causing characteristic triphasic color change.
• Classic triphasic response (in order):
  1. Pallor (white): Vasospasm → digital ischemia → white/pale digits.
  2. Cyanosis (blue): Stagnant blood → deoxygenation → blue discoloration.
  3. Erythema (red): Reactive hyperemia on rewarming → red/flushed digits.
• Not all three phases always present; biphasic (pallor + erythema or cyanosis + erythema) common.
• Well-defined demarcation between affected and normal skin.

• Primary Raynaud's (Raynaud's Disease):
  • No identifiable underlying cause; idiopathic vasospasm.
  • Young women (15-30 years); bilateral and symmetric.
  • Mild; no tissue injury; no digital ulcers or gangrene.
  • Normal nail fold capillaroscopy; negative ANA; no other connective tissue disease features.
  • Good prognosis; may improve with age.
  • Prevalence: 3-5% of general population; higher in colder climates.
• Secondary Raynaud's (Raynaud's Syndrome/Phenomenon):
  • Due to an identifiable underlying disease or condition.
  • Typically older onset; often asymmetric; more severe; may cause digital ulcers, pitting scars, gangrene.
  • Abnormal nail fold capillaroscopy (capillary dropout, giant capillaries = connective tissue disease).
  • Positive ANA in connective tissue disease.
  • Requires investigation and treatment of underlying cause.

• Systemic sclerosis (scleroderma): Most common cause; Raynaud's is often the first manifestation; sclerodactyly, telangiectasia, calcinosis (CREST syndrome); digital ulcers, ischemic pitting scars; nail fold capillary changes.
• Mixed connective tissue disease (MCTD): Second most common.
• Systemic Lupus Erythematosus (SLE).
• Rheumatoid arthritis.
• Sjögren's syndrome.
• Polymyositis/dermatomyositis.

• Thromboangiitis obliterans (Buerger's disease): Young male smokers.
• Atherosclerosis / PAD.
• Fibromuscular dysplasia.
• Vasculitis (Takayasu's, polyarteritis nodosa).
• Thoracic outlet syndrome.
• Subclavian artery disease.

• Beta-blockers (reduce peripheral vasodilation by blocking beta-2 receptors).
• Ergotamine.
• Bleomycin, cisplatin (chemotherapy).
• Vinyl chloride, silica (occupational).
• Cocaine, amphetamines.
• Nicotine (smoking).

• Cryoglobulinemia.
• Polycythemia vera.
• Cold agglutinin disease.
• Paraproteinemia.

• Hypothyroidism.
• Pheochromocytoma.

• Vibration-induced Raynaud's (vibration white finger): Jackhammer, chainsaw operators; HAV (hand-arm vibration) syndrome.

• Episodic attacks lasting 15-30 minutes.
• Triggered by cold exposure (even mild cold such as air conditioning) and emotional stress.
• Digits most commonly affected (fingers > toes); earlobes, nose, tongue occasionally.
• Usually bilateral; asymmetric in secondary RP.
• Pain, numbness, tingling during attack; throbbing pain on rewarming.
• In secondary RP: Digital ulcers (fingertip, over bony prominences), pitting scars (healed digital ulcers), gangrene (severe cases); digital ischemic changes.

• Confirmed if patient describes classic color changes in response to cold/stress.
• Validated questionnaire (Raynaud's Condition Score).
• Provocative cold challenge test (cold water immersion): Objective measurement of digital blood flow before and after cold; skin temperature recovery time prolonged in RP.

• Nail fold capillaroscopy (most important investigation):
  • Primary RP: Normal capillary pattern.
  • Secondary RP (scleroderma pattern): Giant/dilated capillaries, hemorrhages, avascular areas (capillary dropout), architectural disorganization.
• ANA (antinuclear antibody): Positive in connective tissue disease.
• Specific antibodies:
  • Anti-Scl-70 (anti-topoisomerase I): Diffuse scleroderma.
  • Anti-centromere antibody: Limited scleroderma (CREST); highest risk of RP progressing to systemic sclerosis.
  • Anti-dsDNA, anti-Sm: SLE.
  • Anti-Ro/La: Sjögren's syndrome.
  • Anti-U1-RNP: MCTD.
  • RF, anti-CCP: RA.
• CBC: Polycythemia, anemia.
• ESR, CRP: Inflammatory conditions.
• Thyroid function tests: Hypothyroidism.
• Cryoglobulins, cold agglutinins: Hematological causes.
• Chest X-ray: Cervical rib (thoracic outlet syndrome).
• Arterial Doppler: Digital arteries obstruction vs. vasospasm.

• Vasospasm (primary RP or secondary with vasospasm): Digital artery opens on warming.
• Obstruction (atherosclerosis, scleroderma with obliterative vasculopathy): Persistent reduction in flow even when warm.

• Avoid cold exposure; wear gloves, warm clothing; heated gloves.
• Avoid smoking (vasoconstrictor).
• Avoid drugs that worsen RP (beta-blockers, ergotamines, OCP if symptomatic).
• Stress management.
• Biofeedback.
• Hand warming techniques.

• Calcium channel blockers (CCBs) - first-line: Nifedipine (sustained release) most commonly used; amlodipine; reduce frequency and severity of attacks by 50-66%; vasodilators acting on peripheral vasculature. Diltiazem if DHP CCB not tolerated.
• Phosphodiesterase-5 inhibitors (sildenafil, tadalafil): Used for secondary RP, especially scleroderma-related; vasodilation via NO pathway; reduce frequency and duration; effective for digital ulcers healing.
• Topical nitrates (glyceryl trinitrate cream/patch): Applied to finger web spaces; local vasodilation; effective but headache limits use.
• Losartan (ARB): May be used.
• Fluoxetine (SSRI): Some evidence; inhibits platelet serotonin release.
• IV Iloprost (prostacyclin analogue): For severe secondary RP with digital ulcers or critical digital ischemia; infused over 3-5 days; promotes healing; reduces frequency of attacks.
• Endothelin receptor antagonists (bosentan): Reduces new digital ulcer formation in scleroderma (not healing of existing ulcers).
• Alpha-adrenergic blockers (prazosin): Second-line; reduce vasospasm.
• Statins: Anti-inflammatory; endothelial protection; adjunct in secondary RP.

• Digital sympathectomy (adventitial stripping/microsurgical periarterial sympathectomy): For severe, refractory cases with digital ischemia/ulcers; strips adventitia (sympathetic fibers) from digital arteries; reserved for critical ischemia.
• Botulinum toxin (botox) injection: Into digital artery adventitia; blocks sympathetic vasoconstriction; emerging evidence; effective for severe refractory RP.
• Cervical sympathectomy: For upper limb involvement; provides temporary relief only; not recommended due to relapse.

• Wound care; debridement.
• IV prostacyclin (iloprost).
• Antibiotics if infected.
• Bosentan (prevents new ulcers).
• PDE5 inhibitors.
• Surgical debridement + revascularization in critical ischemia.
• Amputation as last resort.

---

Q24. Thromboangiitis Obliterans (Buerger's Disease)

• Thromboangiitis obliterans (TAO), also called Buerger's disease, is a segmental, non-atherosclerotic, inflammatory occlusive disease of small and medium-sized arteries and veins of the distal extremities, strongly associated with tobacco use.
• Almost exclusively in smokers; cessation of smoking is the only definitive treatment.

• Predominantly young males (peak age 20-45 years); though female incidence increasing with increased female smoking.
• Male:female ratio approximately 7:1 to 9:1.
• Higher prevalence in Middle East, Asia, and Eastern Europe (areas with higher tobacco use).
• Not associated with traditional cardiovascular risk factors (no HTN, DM, hyperlipidemia in typical patient).

• Strongly associated with heavy tobacco use (cigarettes, cigars, pipe tobacco, chewing tobacco, and even passive smoking); nicotine metabolites directly toxic to endothelium.
• Immune mechanisms: Anti-endothelial cell antibodies; T-cell mediated; HLA-A9 and HLA-B5 association.
• Hypercoagulable state: Abnormal response to collagen; abnormal platelet function.
• Distinct pathology:
  • Acute phase: Highly cellular, inflammatory thrombus with microabscesses; intact internal elastic lamina (unlike vasculitis where IEL is destroyed - key pathological distinction); panmural inflammation.
  • Subacute phase: Organization of thrombus; inflammatory cells in thrombus.
  • Chronic/healed phase: Dense fibrous recanalization; recannalized thrombus; occlusion.
• Spares large vessels (unlike atherosclerosis).
• Affects infrapopliteal arteries (below knee) and small forearm arteries; may involve coronary, cerebral, mesenteric, renal arteries (rare).

• Ischemic rest pain: Most common presentation; severe burning/aching pain in digits/feet, worse at night and with elevation; constant.
• Digital ulcers: Non-healing, painful ulcers on fingertips or toe tips; punched-out appearance.
• Digital gangrene: Dry or wet; toes and fingers; often requires amputation.
• Intermittent claudication: Calf, foot, or forearm claudication; often arch of foot (plantar claudication - a hallmark; not seen in atherosclerotic PAD which typically causes calf claudication).
• Raynaud's phenomenon: Episodic pallor-cyanosis-erythema in affected digits; present in >44% of TAO patients.

• Migratory superficial thrombophlebitis: Recurrent, painful, red, tender nodular cord along superficial veins; migrates to new sites; classic feature of TAO; helps distinguish from atherosclerotic PAD.
• Cord-like induration along vein course.

• Radial or ulnar artery occlusion; finger ischemia; upper limb claudication.
• Allen's test abnormal: Compress radial artery → ulnar circulation does not maintain perfusion → ulnar artery occlusion.

1. Smoking history.
2. Onset before age 50.
3. Infrapopliteal arterial occlusion (below knee involvement).
4. Upper limb involvement OR migratory superficial thrombophlebitis.
5. Absence of atherosclerotic risk factors other than smoking.

• Atherosclerotic PAD: Older age; risk factors (DM, HTN, hyperlipidemia); proximal involvement; no thrombophlebitis.
• Peripheral embolism (cardiac source): AF, endocarditis; source identified.
• Autoimmune vasculitis: Anti-neutrophil cytoplasmic antibody (ANCA) positive.
• Scleroderma/MCTD: Connective tissue disease features.
• Hypercoagulable states: Protein C/S deficiency, antiphospholipid syndrome.
• Raynaud's disease.
• Takayasu's arteritis: Large vessel involvement.

• History of heavy tobacco use + distal extremity ischemia + age <50 + migratory thrombophlebitis = high clinical suspicion.

• Allen's test: Assesses radial and ulnar artery patency at wrist; abnormal (positive) in upper limb TAO (ulnar or radial artery occlusion).
• ABI: May be normal (distal disease below ABI measurement points) or low if popliteal involved.
• Toe-brachial index (TBI): More sensitive for distal disease; TBI <0.7 = significant distal ischemia.
• Segmental pressure measurements and pulse volume recordings.
• Transcutaneous oxygen (TcPO2): Measures tissue oxygenation; useful for assessing healing potential and severity.

• Digital subtraction angiography (DSA) or CTA/MRA:
  • Characteristic findings (Olin criteria): Segmental occlusions in distal, infrapopliteal arteries (tibial, peroneal, digital arteries); "corkscrew collaterals" (tortuous, coiled collateral vessels bridging segments of occlusion - pathognomonic of TAO); sparing of large proximal vessels; normal appearing vessel wall between skip lesions; no atherosclerotic plaque.
  • Symmetric involvement (bilateral lower limbs often).
• Echocardiography + cardiac workup: To rule out cardiac source of emboli (must exclude cardiogenic embolism).

• Routine labs: CBC, CMP, lipid panel, HbA1c, ESR, CRP, ANA, ANCA, RF.
• Purpose: To exclude other conditions (all should be normal in TAO).
• Hypercoagulable panel: Protein C, S, antithrombin III, factor V Leiden, antiphospholipid antibodies.
• Biopsy of superficial thrombophlebitis lesion: Histopathology shows acute phase lesion (inflammatory thrombus, intact IEL, microabscesses within thrombus) = pathognomonic; rarely needed but confirms diagnosis.

• Complete cessation of all tobacco products is the only effective treatment to halt disease progression. Even one cigarette per day perpetuates disease.
• Amputation rates dramatically reduced with cessation: ~0% in non-smokers vs ~40% in continued smokers.
• Nicotine replacement therapy (NRT) is controversial (nicotine may perpetuate disease); use non-nicotine cessation aids (varenicline, bupropion) if possible.

• Aspirin: Antiplatelet; reduces thrombotic events; mainstay.
• Anticoagulation (heparin/warfarin): For acute thrombosis; not for chronic stable disease.
• Iloprost (IV prostacyclin analogue): Reduces pain at rest and ulcer size; bridges patients to cessation of smoking; improves healing; significantly reduces amputation rates.
• Cilostazol: PDE3 inhibitor; vasodilator + antiplatelet; may improve claudication.
• Calcium channel blockers: For Raynaud's component.
• Statins: Anti-inflammatory; possible benefit even in non-dyslipidemic patients.
• Analgesia: For ischemic rest pain; opioids may be required; regional nerve blocks.
• Wound care: Meticulous care of digital ulcers; prevent infection.

• PTA/Angioplasty: Limited role due to diffuse distal involvement; tried when feasible segment available.
• Surgical bypass: Poor distal targets; bypass not usually feasible or durable; exception: if adequate distal target vessel available.
• Sympathectomy (lumbar or digital): Reduces vasospasm; improves blood flow; temporary relief; may help wound healing; last resort.
• Spinal cord stimulation: For refractory ischemic pain and ulcers; modulates pain and increases peripheral blood flow.
• Bone marrow mononuclear cell/stem cell therapy: Experimental; angiogenic growth factors; some promising results.
• Amputation: Inevitable in many patients who continue to smoke; digit amputation most commonly; below-knee or above-knee amputation in severe cases.

---

Q25. Deep Venous Thrombosis (DVT) and Its Complications

• Deep venous thrombosis (DVT) is thrombosis (blood clot formation) within the deep venous system.
• Most common in lower extremities (90%): Calf veins (below knee) and/or proximal veins (popliteal, femoral, iliac).
• Upper extremity DVT: Axillary-subclavian veins; accounts for ~10%; increasing with central venous catheters.

1. Venous stasis: Immobility (long flights, hospitalization, bed rest), varicose veins, heart failure, obesity, pregnancy.
2. Endothelial injury/dysfunction: Surgery, trauma, central venous catheter, IV drug use, vasculitis.
3. Hypercoagulability: Inherited (Factor V Leiden - most common inherited thrombophilia; Prothrombin G20210A mutation; Protein C/S deficiency; Antithrombin III deficiency); acquired (malignancy, antiphospholipid syndrome, pregnancy, OCP/HRT, heparin-induced thrombocytopenia, nephrotic syndrome).

• Immobility: Bed rest >3 days; long-distance travel (>4 hours flight/car); paralysis.
• Surgery (especially orthopedic - total hip/knee replacement, hip fracture surgery).
• Major trauma.
• Malignancy (hypercoagulable state + stasis; also Trousseau syndrome: migratory thrombophlebitis associated with occult malignancy).
• Pregnancy and postpartum period.
• Oral contraceptive pills / hormone replacement therapy.
• Prior DVT or PE (strongest individual risk factor for recurrence).
• Advanced age.
• Obesity (BMI >30).
• Heart failure, MI, respiratory failure (stasis).
• Inflammatory bowel disease.
• Inherited thrombophilias.
• Central venous catheters / pacemaker leads.
• Varicose veins.

• May be asymptomatic (50%); discovered incidentally or only when PE occurs.
• Unilateral leg pain: Aching, cramping; calf most common location.
• Swelling: Unilateral pitting edema; entire limb if iliofemoral DVT.
• Warmth and erythema over affected limb.
• Dilated superficial veins (collateral venous drainage).
• Low-grade fever.
• Homan's sign (dorsiflexion of foot causing calf pain): Historically used; poor sensitivity (~50%) and specificity (~40%); should NOT be relied upon; can dislodge thrombus; NOT routinely recommended.
• Phlegmasia cerulea dolens (massive iliofemoral DVT): Extreme edema, cyanosis, venous gangrene; threatened limb; arterial compromise from massive venous occlusion → surgical/catheter-directed thrombolysis emergency.
• Phlegmasia alba dolens: Whitish edema; massive DVT without cyanosis; "milk leg"; associated with pregnancy.

• Arm swelling, pain, heaviness.
• Pitting edema of forearm/hand.
• Distended collateral veins over chest/shoulder.
• "Effort thrombosis" (Paget-Schroetter syndrome): Young athletes (rowers, swimmers, throwers); axillary-subclavian DVT from repetitive arm motion + thoracic outlet compression.

• ≥2 = High probability; 1 = Moderate; ≤0 = Low.

• Compression ultrasound (CUS) - first-line imaging: Non-invasive, widely available; non-compressibility of vein = DVT; sensitivity 95% proximal DVT; 70-80% for calf DVT; B-mode + color Doppler + spectral analysis.
• D-dimer: High sensitivity (~95%), low specificity; age-adjusted cutoff (age × 10 µg/L in patients >50 years); useful for ruling OUT DVT in low-probability patients; elevated in many conditions (cancer, infection, surgery, pregnancy).
• Algorithm: Calculate Wells score → Low/moderate + D-dimer negative = DVT excluded; High probability = proceed directly to ultrasound; Low/moderate + D-dimer positive = ultrasound.
• CT venography / MR venography: For pelvic, IVC, upper extremity, or inconclusive ultrasound; superior for central veins.
• Contrast venography: Historical gold standard; rarely needed; invasive; replaced by CUS.
• Thrombophilia workup: For unexplained, recurrent, or unusual site DVT (cerebral sinus, mesenteric veins); Factor V Leiden, prothrombin mutation, antithrombin III, protein C/S, antiphospholipid antibodies, homocysteine. Best tested ≥3 months after event (acute DVT itself reduces protein C/S levels).
• Cancer screening: Unprovoked DVT warrants age-appropriate cancer screening (colonoscopy, PSA, CT abdomen/pelvis, mammography).

• Goal: Prevent clot propagation, prevent PE, reduce post-thrombotic syndrome.
• NOACs (Direct oral anticoagulants) - preferred:
  • Rivaroxaban (Xarelto): 15 mg BID x 21 days, then 20 mg OD.
  • Apixaban (Eliquis): 10 mg BID x 7 days, then 5 mg BID (preferred; lowest bleeding risk).
  • Dabigatran or edoxaban: Require initial parenteral anticoagulation.
• Low-molecular-weight heparin (LMWH): Enoxaparin 1 mg/kg SC BID or 1.5 mg/kg OD; first-line in pregnancy (NOACs contraindicated), malignancy-associated DVT (rivaroxaban or LMWH equivalent), and inpatient settings; preferred in renal failure.
• Warfarin: INR 2-3; requires bridging with LMWH/UFH; less convenient but cost-effective; used when NOACs unavailable or contraindicated.
• Duration:
  • Provoked (reversible risk factor) DVT: 3 months.
  • Unprovoked proximal DVT: Minimum 3 months; consider indefinite anticoagulation.
  • Unprovoked distal (calf) DVT: 6 weeks to 3 months.
  • Cancer-associated DVT: Indefinite (until cancer in remission).
  • Recurrent DVT: Indefinite.

• Below-knee graduated compression stockings (30-40 mmHg): Reduce symptoms and post-thrombotic syndrome (PTS); start early; wear for ≥2 years.

• For massive iliofemoral DVT with severe limb ischemia (phlegmasia cerulea dolens) or significant symptom burden in young patients.
• Alteplase infused through catheter directly into thrombus; pharmacomechanical CDT.
• Reduces PTS incidence in selected patients.
• Risk: Major bleeding; contraindicated if recent surgery/stroke.

• For patients with contraindication to anticoagulation + acute PE or proximal DVT.
• Preventable PE when anticoagulation fails.
• Retrievable filters preferred (retrieve when anticoagulation can be restarted).
• NOT for routine DVT prophylaxis.

• Thrombus detaches → travels through right heart → pulmonary arteries → obstruction → pulmonary infarction, RV failure, hypoxemia, sudden death.
• Proximal DVT (popliteal and above) → high embolization risk.
• Calf DVT alone → low risk but propagates to proximal in ~25%.
• PE occurs in 30-50% of untreated proximal DVT.
• Massive PE → hemodynamic instability → shock → cardiac arrest.

• Chronic venous insufficiency from valvular incompetence due to thrombus-induced valve damage + residual venous obstruction.
• Incidence: 20-50% of proximal DVT within 2 years.
• Features: Chronic pain, swelling, heaviness, varicosities, skin changes (lipodermatosclerosis, hyperpigmentation), venous ulcers; worse with standing/walking; improves with elevation.
• Villalta score: Grades PTS severity (symptoms + signs); score ≥5 = PTS; ≥15 = severe PTS.
• Prevention: Adequate anticoagulation; compression stockings.

• After stopping anticoagulation; higher risk with unprovoked DVT, residual thrombus, thrombophilia, cancer.
• 30% risk at 5 years for unprovoked DVT.

• In patients with patent foramen ovale (PFO) or ASD → venous thrombus crosses to left heart → systemic arterial embolism → stroke, limb ischemia, mesenteric ischemia.

• Massive thrombosis of entire venous outflow → arterial compromise → tissue necrosis → limb loss.
• Emergency: CDT, thrombectomy.

• Risk assessment for all hospitalized patients.
• Pharmacological prophylaxis: LMWH (enoxaparin 40 mg OD SC), fondaparinux, NOAC (rivaroxaban 10 mg/day); for high-risk surgical patients, medical patients with restricted mobility.
• Mechanical prophylaxis: Graduated compression stockings; intermittent pneumatic compression devices (IPC/sequential compression devices/SCDs) - preferred when anticoagulation contraindicated.
• Early ambulation post-surgery.
• Hydration.
• Prolonged prophylaxis post-orthopedic surgery (hip/knee arthroplasty): 35 days post-THR; 14 days post-TKR.

---

Q26. Chronic Venous Insufficiency and Postphlebitic Syndrome

• Chronic venous insufficiency (CVI) is a condition in which the leg veins cannot pump enough blood back to the heart due to impaired venous valve function, venous obstruction, or both.
• Characterized by persistent venous hypertension in the lower limb.
• A spectrum ranging from telangiectasias (CEAP C1) to active venous ulcers (CEAP C6).

• Primary CVI: Idiopathic valve incompetence; no prior DVT; genetic predisposition; congenital valve absence.
• Secondary CVI: Consequence of DVT (post-thrombotic syndrome) - most common identifiable cause; thrombosis → valve damage + partial obstruction → persistent venous hypertension.
• Congenital CVI: Absent or malformed deep venous valves; Klippel-Trenaunay syndrome.

• Incompetent valves → venous reflux → standing column of blood from the heart to legs → chronic venous hypertension in calf perforating veins (normal pressure <35 mmHg; in CVI elevated to >90 mmHg).
• Venous hypertension → distension of capillaries → plasma leakage → interstitial edema → leukocyte activation → inflammatory cascade → tissue damage → skin changes → ulceration.
• Fibrin cuff theory: Fibrin deposits around capillaries → impair diffusion of O2 and nutrients → chronic skin ischemia.
• Hemosiderin deposition: RBC extravasation → hemoglobin breakdown → brown pigmentation.

• Prior DVT (most important; post-thrombotic).
• Family history of varicose veins.
• Female sex; multiparity.
• Obesity.
• Prolonged standing (occupational: nurses, teachers, chefs).
• Sedentary lifestyle; lack of calf muscle pump.
• Advanced age.
• Lower extremity trauma.
• Prior venous surgery.

• Leg heaviness and aching: Worse with prolonged standing; worse at end of day; better with elevation.
• Leg swelling (edema): Pitting; worse in evenings; better overnight.
• Itching (pruritus) over varicosities or skin changes.
• Burning or throbbing pain.
• Restless leg syndrome association.
• Venous claudication (bursting calf pain with walking; slowly relieved by rest AND elevation).

• Varicose veins: Dilated, tortuous, visible superficial veins; great saphenous vein (medial, knee to groin) or small saphenous vein (posterior calf) distribution.
• Edema: Pitting; initially reversible; later non-pitting with fibrosis.
• Skin changes:
  • Hyperpigmentation (brown discoloration): Hemosiderin deposits from red cell extravasation; characteristically at medial malleolus ("gaiter area").
  • Stasis dermatitis (venous eczema): Erythematous, scaly, pruritic rash.
  • Lipodermatosclerosis: Chronic skin and subcutaneous tissue fibrosis; "inverted champagne bottle" or "inverted bottle" appearance of lower leg (tight, indurated, hyperpigmented skin; narrowing at ankle with edema above).
  • Atrophie blanche: White, atrophic, scarred areas with red dots; avascular skin; high ulcer risk.
  • Corona phlebectatica: Fan-shaped clusters of telangiectasias around medial/lateral malleolus.
• Venous ulcers:
  • Most common at medial malleolus (gaiter area).
  • Shallow, irregular borders; moist, exudative base with granulation tissue.
  • Surrounding lipodermatosclerosis and hyperpigmentation.
  • Moderately painful (compared to very painful arterial ulcers); pain improves with elevation.
  • May be large; chronic/recurrent.
  • Not over bony prominences (unlike arterial and neuropathic ulcers).

• Chronic syndrome of CVI occurring specifically after DVT.
• Mechanism: DVT → valve destruction + persistent venous outflow obstruction → chronic venous hypertension.
• Develops in 20-50% of patients after proximal DVT.
• Begins 1-2 years after DVT.
• Features identical to CVI (see above) but with known prior DVT history.
• Villalta score for severity.
• Severe cases: Disabling swelling, intractable ulceration, severe pain.

• Duplex venous ultrasound (first-line and most important):
  • Assesses venous anatomy, reflux, obstruction, residual thrombus.
  • Valve incompetence: Reflux >500 ms (superficial), >1000 ms (deep) on Valsalva or manual compression-release.
  • Identifies saphenofemoral junction (SFJ) incompetence, great saphenous vein reflux, deep vein obstruction.
• Air plethysmography (APG): Quantifies calf muscle pump function and venous reflux; functional assessment.
• Ambulatory venous pressure (AVP) measurement: Invasive; gold standard physiologic assessment; rarely needed clinically.
• CT venography / MR venography: For central venous obstruction (iliac, IVC); May-Thurner syndrome (left iliac vein compression by right iliac artery).
• IVUS (intravascular ultrasound): Best assessment of iliac vein compression; endovascular planning.

• Compression therapy (cornerstone):
  • Graduated elastic compression stockings (ECS): 20-30 mmHg (mild-moderate CVI); 30-40 mmHg (severe CVI); knee-high usually sufficient; must be worn daily, all day.
  • Multi-layer compression bandaging: For active ulcers; Unna boot (zinc oxide impregnated gauze) + elastic bandage or 4-layer bandage system.
  • Pneumatic intermittent compression devices: For severe edema or ulcers refractory to bandaging.
• Leg elevation: Above heart level; 30 min 3-4 times daily; reduces venous pressure.
• Calf muscle exercise: Walking; ankle range of motion; strengthens calf muscle pump.
• Weight reduction.
• Wound care for ulcers: Moist wound environment; debridement; biological dressings.
• Antibiotics: Only if superinfected (cellulitis); not routinely.
• Venoactive drugs (phlebotonic agents):
  • Diosmin/hesperidin (micronized purified flavonoid fraction - MPFF): Reduces capillary permeability; reduces edema and symptoms; approved in Europe.
  • Horse chestnut seed extract (aescin).
  • Rutosides (troxerutin).

• Endovenous ablation of incompetent saphenous vein:
  • Endovenous laser ablation (EVLA/EVLT): Laser fiber destroys vein wall; outpatient; preferred.
  • Radiofrequency ablation (RFA/VNUS ClosureFast): Thermal energy; similar to EVLA; slightly less postoperative pain.
  • Both: Replace surgical saphenous vein stripping; equally effective; lower complication rates.
• Foam sclerotherapy: Injection of sclerosant foam; obliterates varicose veins and incompetent tributaries; less effective than thermal ablation for GSV trunk.
• Surgical stripping: Saphenofemoral ligation + stripping; historical gold standard; now largely replaced by endovenous techniques.
• Venous ulcer surgery: Ablation of refluxing veins accelerates ulcer healing and reduces recurrence.
• Deep venous reconstruction: For post-thrombotic obstruction; iliac vein stenting (May-Thurner/NIVL); venous bypass; valvuloplasty; valve transplant (experimental).
• Skin grafting: For non-healing large venous ulcers.

---

Q27. Superficial Venous Thrombosis and Its Complications

• Superficial venous thrombosis (SVT), also called superficial thrombophlebitis, is thrombosis of a superficial vein accompanied by inflammation of the overlying skin.
• Most commonly affects the great saphenous vein (GSV) system.
• Historically considered benign; now recognized as potentially serious condition with DVT and PE complications.

• Varicose veins: Most common underlying condition (60-80% of SVT occurs in varicose veins).
• Female sex.
• Prior DVT or PE.
• Thrombophilia (inherited hypercoagulable states): Higher rate of concomitant DVT and PE.
• Malignancy (especially Trousseau syndrome: migratory thrombophlebitis, recurrent SVT at different sites = may be sign of occult cancer - pancreatic, gastric, lung).
• Pregnancy and postpartum.
• OCP/HRT.
• Intravenous catheter: Post-IV catheter thrombophlebitis; mechanical or chemical injury.
• IV drug use.
• Trauma, surgery.
• Long-distance travel.
• Buerger's disease (TAO): Migratory superficial thrombophlebitis is a hallmark.
• Mondor's disease: SVT of thoracoepigastric or lateral thoracic vein; presents as tender cord on anterior chest wall or breast.
• Behcet's disease: Recurrent SVT + deep vein thrombosis + arterial occlusion.

• Septic (suppurative) thrombophlebitis: IV catheter → bacterial infection of venous wall → suppuration → bacteremia → sepsis; most common organisms: Staphylococcus aureus, coagulase-negative Staph, Gram-negatives.
• Aseptic (sterile) thrombophlebitis: No infection; inflammatory response to clot; most common.
• Chemical thrombophlebitis: Irritant IV fluids (hypertonic glucose, potassium, chemotherapy) → endothelial injury.
• Migratory thrombophlebitis (Trousseau's syndrome): Recurrent, at different sites; associated with cancer.

• Erythema: Redness along course of vein; linear pattern.
• Tenderness: Localized pain and tenderness along vein.
• Warmth: Local heat.
• Palpable cord: Tender, indurated, rope-like thickening along vein course; most specific finding.
• Swelling: Local edema around affected vein; rarely extends to entire limb (if limb-wide edema → DVT must be excluded).
• Fever: Low-grade; high fever suggests septic thrombophlebitis.
• Usually well-demarcated, localized to vein distribution.
• Symptoms peak 1-2 weeks then gradually resolve.
• May leave persistent brown discoloration along vein course (hemosiderin).

• SVT extending to within 3 cm of saphenofemoral junction (SFJ) → high risk of DVT extension into deep venous system → PE risk.
• DVT coexists with SVT in ~20-25% of cases (concomitant deep thrombosis).
• PE occurs in SVT: ~4-7% (not truly benign).

• Usually clinical diagnosis (erythema, tenderness, palpable cord along a vein).

• Duplex venous ultrasound: Mandatory to:
  1. Confirm SVT diagnosis and extent.
  2. Exclude concomitant DVT (present in 20-25%).
  3. Assess proximity to SFJ (if ≤3 cm from junction → higher risk; some recommend anticoagulation).
  4. Map the extent of thrombosis.
• Serial ultrasound: To assess for propagation.

• D-dimer: Elevated; non-specific; useful to guide need for DVT workup in low-probability cases.
• CBC: Leukocytosis if septic.
• Blood cultures: If septic thrombophlebitis suspected.
• Thrombophilia screen: In young patients, recurrent, unusual sites.
• Cancer screen: If migratory thrombophlebitis (Trousseau's syndrome).

• Extension to deep venous system → DVT: 20-25% risk; thrombus propagates through perforating veins or through SFJ.
• Pulmonary embolism: PE risk ~4-7% (previously underestimated); higher if SVT involves GSV proximally or coexists with DVT.
• Septic thrombophlebitis: Septicemia, bacterial endocarditis, metastatic infection; high mortality if untreated.
• Skin necrosis: Over inflamed vein.
• Recurrent SVT: Especially in varicose veins or thrombophilia.
• Post-thrombotic changes: Hyperpigmentation, induration, vein obliteration.
• Limb loss (rare): In septic cases with arterial involvement.

• Elevation of affected limb.
• Warm compresses or anti-inflammatory gels (diclofenac gel) locally: Reduce inflammation and pain.
• Ambulation encouraged (unlike DVT where rest was previously recommended).
• NSAIDs (topical or systemic): Reduce pain and inflammation; e.g., diclofenac gel topically or oral ibuprofen.

• Fondaparinux 2.5 mg SC once daily x 45 days: Treatment of choice for extensive SVT of GSV (length ≥5 cm); prevents DVT/PE; CALISTO trial demonstrated superior efficacy vs. placebo; prevents propagation and thromboembolic complications.
• LMWH (intermediate or prophylactic dose): Alternative to fondaparinux; enoxaparin 40 mg/day or therapeutic dose; used for SVT close to SFJ or with concomitant DVT.
• Anticoagulation (full therapeutic): If SVT extends to within 3 cm of SFJ, OR concurrent DVT/PE present; treat as DVT with full anticoagulation for 3 months.
• Topical heparin cream: Mild benefit for small SVT; limited evidence.
• Antibiotics: IV antibiotics (anti-staphylococcal - vancomycin/flucloxacillin) for septic thrombophlebitis; remove IV catheter; surgical drainage if suppuration; aggressive management to prevent bacteremia.

• High ligation of GSV at SFJ: Prevents extension into deep system when SVT approaches or reaches SFJ; increasingly replaced by anticoagulation.
• Thrombectomy (Stab avulsion): For localized accessible thrombus; pain relief.
• Treat underlying varicose veins after acute episode resolves: Ablation to prevent recurrence.

---

Q28. Varicose Veins and Idiopathic Telangiectasia

• Varicose veins are abnormally dilated, tortuous, elongated superficial veins; ≥3 mm in diameter in the standing position.
• Most commonly affect the great saphenous vein (GSV) and small saphenous vein (SSV) systems in the legs.
• Part of the chronic venous disease spectrum (CEAP C2).

• Extremely common: Affects ~23% of adults in developed countries.
• Female > male (up to 3:1); hormonal influences.
• Prevalence increases with age, pregnancy, parity.

• Primary varicose veins (most common): Intrinsic weakness of venous wall and valves; genetic predisposition.
• Secondary varicose veins: Due to deep venous obstruction (post-thrombotic) causing increased superficial venous pressure; pelvic mass compressing IVC/iliac veins; AV fistula (causes secondary dilated veins).
• Risk factors:
  • Family history: ~70-80% with varicose veins have positive family history; autosomal dominant with variable penetrance.
  • Female sex and multiparity: Progesterone relaxes smooth muscle; increased blood volume.
  • Pregnancy: Increased venous pressure from gravid uterus; hormonal effects.
  • Prolonged standing/sitting: Occupational (nurses, teachers, surgeons).
  • Obesity.
  • Age.
  • Low-fiber diet/constipation (increased abdominal straining).
  • Prior DVT (secondary).

• Incompetent valves (saphenofemoral junction or sapheno-popliteal junction most often) → reflux of blood distally → raised superficial venous pressure → veins dilate → tortuosity → further valve failure → progressive worsening.
• "Descending theory": Valve failure starts at SFJ and propagates distally.

• Aching, heaviness, and fatigue in legs (especially after prolonged standing).
• Itching (pruritus) over varicosities.
• Throbbing or burning sensation.
• Swelling at end of day.
• Cramps (nocturnal leg cramps).
• Restless legs.
• All symptoms worse with heat, prolonged standing; better with cold, elevation, exercise.

• Dilated, tortuous, rope-like veins visible under skin; blue-green color.
• Palpable thickened, tortuous cord-like vessels.
• Edema (mild, ankle).
• Hemosiderin pigmentation (if long-standing; CVI developing).
• Varicose eczema (stasis dermatitis).
• Associated telangiectasias and reticular veins.
• Saphena varix: Blowing, soft dilatation at SFJ in groin; empties on lying down; transmits cough impulse; saphenous vein thrill with coughing.

• Trendelenburg test: Assess SFJ and perforator incompetence (see Q15 Peripheral Vascular Examination techniques).
• Perthes test: Assess deep vein patency.
• Cough impulse test: Press at SFJ; palpable impulse on cough = valve incompetence.
• Modified Trendelenburg: Identify level of incompetence with tourniquet at different levels.

• Superficial thrombophlebitis (10-20% of untreated varicose veins).
• Bleeding: Rupture of varicosity; can be severe; apply direct pressure, elevate.
• Venous eczema / stasis dermatitis.
• Lipodermatosclerosis.
• Venous ulceration (C6 CEAP; occurs in ~1% of population with varicose veins).
• Hemorrhage into varicosity.
• Hyperpigmentation.
• Cosmetic embarrassment.

• Clinical examination + Duplex venous ultrasound:
  • Maps GSV and SSV.
  • Identifies SFJ and SPJ incompetence (reflux duration >500 ms = significant).
  • Identifies deep venous reflux or obstruction (important before treatment).
  • Identifies perforator incompetence.
• CTV/MRV: For pelvic vein incompetence (gonadal vein reflux causing vulval varicosities), May-Thurner syndrome.

• Compression stockings (20-30 mmHg): First-line for mild symptoms; reduce symptoms but do not eliminate varicosities.
• Leg elevation.
• Weight loss.
• Exercise (calf pump).

• Endovenous Laser Ablation (EVLA/EVLT): Gold standard; laser fiber inserted into GSV under ultrasound guidance → thermal ablation of vein wall; success rate >90%; outpatient; local anesthesia; quick recovery.
• Radiofrequency Ablation (RFA/VNUS ClosureFast): Thermal ablation by radiofrequency; similar efficacy to EVLA; slightly less pain/bruising.
• Foam Sclerotherapy: Injection of sclerosant (sodium tetradecyl sulfate or polidocanol) as foam into vein; obliterates vein; used for GSV (UGFS - ultrasound-guided foam sclerotherapy) or tributaries; less effective than thermal ablation for GSV trunk.
• Ambulatory phlebectomy (stab avulsion): Removal of tributaries through tiny skin punctures; used alongside ablation for tributaries.
• Surgical stripping (Trendelenburg operation): Flush ligation at SFJ + GSV stripping; historical gold standard; now largely replaced by endovenous techniques; more complications, longer recovery.
• Cyanoacrylate glue (VenaSeal): Non-thermal; no tumescent anesthesia needed; glue injected seals vein.
• Mechanochemical ablation (ClariVein): Combined mechanical rotating wire + sclerosant; non-thermal.

---

• Telangiectasias are permanently dilated small superficial blood vessels (capillaries, venules, arterioles) ≤1 mm in diameter, visible as fine red, purple, or blue lines on the skin.
• Also called spider veins, thread veins, or broken capillaries.
• Part of CEAP classification: C1 chronic venous disease.
• "Idiopathic" = no identifiable systemic cause; primary.

• Spider telangiectasias (spider angiomas/nevi): Central arteriole with radiating vessels; blanch with pressure; central pulsation visible; associated with liver disease (cirrhosis), pregnancy, OCP use.
• Mat telangiectasias: Flat, macular collections; often on thighs.
• Linear telangiectasias: Thread-like lines.
• Venous flares (reticular veins): Dilated 2-3 mm intradermal veins, bluish-green; "corona phlebectatica" at ankle.

• Hereditary Hemorrhagic Telangiectasia (HHT / Osler-Weber-Rendu disease): Autosomal dominant; telangiectasias on lips, tongue, fingertips; AVMs in lungs, liver, brain; recurrent epistaxis (most common presenting symptom); GI bleeding.
• Scleroderma/CREST syndrome: Telangiectasias on face, hands, lips (part of CREST: Calcinosis, Raynaud's, Esophageal dysmotility, Sclerodactyly, Telangiectasias).
• Ataxia-telangiectasia (Louis-Bar syndrome): Cerebellar ataxia + oculocutaneous telangiectasias + immunodeficiency.
• Cirrhosis: Spider angiomata (>5 = significant; associated with portal hypertension); palmar erythema.
• Rosacea: Facial telangiectasias.
• Chronic corticosteroid use.
• Radiation-induced telangiectasias.
• Chronic sun exposure (actinic/solar telangiectasias on face).
• Hormonal: Pregnancy, OCP (increased estrogen levels).
• Mastocytosis.

• Most common; predominantly women (90%).
• Related to heredity, prolonged standing, obesity, pregnancy, hormonal factors.
• No systemic disease.
• Cosmetically distressing; minor symptoms (aching, burning, itching).
• CEAP C1.

• Clinical (visual inspection).
• Dermoscopy: Visualization of vessel pattern.
• Duplex ultrasound: To exclude underlying CVI or reticular vein reflux feeding telangiectasias.
• Evaluate for systemic causes if multiple, unusual location, or family history of HHT.

• Sclerotherapy: Most effective and widely used treatment; injection of liquid sclerosant (polidocanol, sodium tetradecyl sulfate, hypertonic saline) directly into telangiectasias; multiple sessions; for larger vessels.
• Laser therapy:
  • Nd:YAG laser (1064 nm): Best for resistant, deeper telangiectasias; effective for leg spider veins.
  • Pulsed dye laser (PDL, 585/595 nm): Best for facial telangiectasias; spider angiomata.
  • Intense Pulsed Light (IPL): Facial telangiectasias; rosacea.
• Thermocoagulation (high-frequency electrocautery): Fine needle; very fine vessels.
• Combined approach: Sclerotherapy + laser; for recalcitrant cases.
• Address underlying venous insufficiency first (ablate reticular veins or GSV incompetence before treating telangiectasias; otherwise will recur).
• HHT management: Epistaxis management (humidification, emollients, laser cauterization, embolization for severe AVMs); iron replacement; bevacizumab (anti-VEGF) for severe cases; genetic counseling.

---

Q29. Arteriovenous Fistula - Etiology, Symptoms and Signs, Differential Diagnosis, Complications, Diagnostic Procedures, etc.

• An arteriovenous fistula (AVF) is an abnormal communication (direct connection) between an artery and a vein, bypassing the normal capillary circulation.
• Results in high-pressure arterial blood flowing directly into the low-pressure venous system.

• Present from birth; due to abnormal vascular development.
• Part of arteriovenous malformations (AVM).
• Hereditary Hemorrhagic Telangiectasia (HHT): Multiple congenital AVMs in lungs, liver, brain, GI tract.
• Klippel-Trenaunay syndrome: AVMs + varicose veins + limb hypertrophy.

• Traumatic (most common): Penetrating trauma (gunshot, stab wound, fracture fragment) → injury to adjacent artery and vein → direct communication.
  • Common sites: Femoral vessels (most common; also a complication of cardiac catheterization), carotid-jugular, subclavian, radial-cephalic.
• Iatrogenic:
  • Post-cardiac catheterization (femoral AVF).
  • Post-renal biopsy (renal AVF).
  • Surgical creation for hemodialysis access: Cimino-Brescia AVF (radial artery to cephalic vein at wrist) - most common site; or brachial artery-based.
• Spontaneous:
  • Ruptured aortic/visceral aneurysm into adjacent vein: Aorto-caval fistula (aorta ruptures into IVC) → massive high-output HF.
  • Ruptured renal artery aneurysm into renal vein.
• Neoplastic: Vascular tumors eroding adjacent vessels.
• Inflammatory/Infectious: Arterial aneurysm eroding into adjacent vein.

• Arterial blood bypasses capillary bed → reduced peripheral resistance in affected limb → compensatory increased CO.
• Proximal arterial flow increases (to supply fistula).
• Distal to fistula: "Steal phenomenon" → reduced arterial pressure and flow → distal ischemia.
• Venous hypertension: High-pressure blood in low-pressure veins → venous dilation, varicosities, limb swelling.
• Chronic large AVF: High-output cardiac failure (Frank-Starling overload).

• Palpable thrill: Continuous vibration over the fistula; felt as a "purring" sensation; pathognomonic.
• Continuous (machinery) bruit: Loudest at fistula; systolic and diastolic components (continues through diastole unlike arterial bruits which are purely systolic); heard with stethoscope over fistula.
• Pulsatile mass: If fistula site is superficial.
• Dilated, pulsatile veins (arterialized veins): Veins visibly enlarged, pulsatile; warm; draining high-pressure blood.
• Local warmth and swelling.
• Scar or wound: If traumatic.

• Distal ischemia: Pallor, coldness, pain, paresthesia, weakness in limb distal to fistula; intermittent claudication.
• Steal syndrome (especially in hemodialysis access fistulae): Hand ischemia; digital gangrene in severe cases; the fistula "steals" blood from distal perfusion.

• High-output heart failure: If large fistula → large volume shunt → increased CO → LV dilation → HF.
• Tachycardia, cardiomegaly, widened pulse pressure, hyperdynamic precordium.
• Venous hypertension proximal to fistula: Edema, varicosities.
• Limb enlargement: In congenital AVMs/fistulae; limb length discrepancy (increased bone growth due to increased blood flow in children).
• Hyperhidrosis (increased sweating) over fistula due to increased blood flow.

• Manual compression of the fistula → sudden reduction in venous return → drop in CO → reflex bradycardia (via baroreceptor reflex); heart rate slows and BP rises.
• Pathognomonic for significant AVF.
• Useful bedside test to confirm AVF diagnosis.

• Arterial aneurysm: Pulsatile mass but no thrill or continuous bruit; no dilated veins.
• Venous aneurysm: Soft, compressible, no pulse.
• Abscess/hematoma: Tender, non-pulsatile; no bruit.
• Soft tissue tumor/sarcoma: Vascular tumor may have bruit; imaging differentiates.
• Lymph node/lymphangioma.
• Glomus tumor: Small, painful subungual mass; no thrill.
• Post-traumatic pseudoaneurysm: Pulsatile, systolic bruit (not continuous); no thrill; no arterialized veins.

• High-output cardiac failure: Most serious systemic complication; ventricular dilation, biventricular failure, pulmonary edema; more common with large, proximal, long-standing AVF.
• Distal ischemia (steal syndrome): Especially after hemodialysis access creation; hand pain, weakness, numbness, ulceration, gangrene.
• Venous hypertension: Distal limb edema, varicosities, venous insufficiency, skin changes, ulceration.
• Limb asymmetry: Congenital AVMs → limb hypertrophy in children (overgrowth due to increased blood flow).
• Hemorrhage: Rupture of arterialized veins or pseudoaneurysm at fistula site.
• Aneurysmal dilation: Artery proximal to fistula dilates (increased flow); vein aneurysm (arterialized vein dilates with pressure).
• Infection: Septic endarteritis; especially traumatic or IV drug-related fistulae.
• Thrombosis of fistula: Especially hemodialysis access; access loss.
• Pulmonary hypertension: Increased pulmonary blood flow → right heart overload.
• Paradoxical embolism: If intracardiac shunt coexists.
• Air embolism: During compression/access of central AVF.

• Duplex Doppler Ultrasound (first-line):
  • Identifies fistula; shows high-velocity, low-resistance, turbulent flow at fistula.
  • Venous side: Arterialized waveform (pulsatile, high-velocity venous flow - normally veins have low-velocity non-pulsatile flow).
  • Measures volume flow (for hemodialysis access adequacy: >600 mL/min = adequate).
  • Color Doppler: "Perivascular tissue vibration artifact" = color aliasing surrounding fistula = highly specific for high-flow fistula.
• CT Angiography (CTA): 3D anatomy; fistula location; feeding arteries; draining veins; planning surgery or embolization.
• MR Angiography (MRA): Excellent soft tissue detail; no radiation; used for complex congenital AVMs; time-of-flight MRA.
• Digital Subtraction Angiography (DSA): Gold standard for anatomy; required pre-operatively for embolization or surgery; direct measurement of flow; most detailed assessment.
• Echocardiography: Assess CO, LV function, and signs of high-output HF if large fistula.
• Contrast venography: For upper extremity AVF or central venous disease.
• Cardiac catheterization: For physiologic assessment in high-output HF; measure CO and pulmonary pressures.
• Isotope ventriculography: CO measurement.

• Deliberately created (Cimino-Brescia or prosthetic graft - PTFE).
• "Fistula first" principle: Native AVF preferred over graft and central venous catheter for HD access.
• Maturation: 6-12 weeks required for "arteriovenous maturation" before use.
• Complications managed with angioplasty (stenosis), thrombolysis/thrombectomy (thrombosis), surgical revision.

• Endovascular treatment (preferred):
  • Covered stent graft: Placed across fistula in artery; excludes fistula while maintaining arterial flow; highly effective for femoral, aorto-caval, renal AVF.
  • Embolization (coil, glue, ONYX): For congenital AVMs; branches embolized; staged for complex lesions.
• Surgical repair:
  • Simple arteriovenous repair: Primary closure of fistulous opening; preferred for small, accessible fistulae.
  • Arterial interposition graft: If significant vessel damage.
  • Ligation: Simple ligation if distal flow preserved.
• Observation: Small, hemodynamically insignificant fistulae (post-catheterization micro-fistulae) may close spontaneously.
• Ultrasound-guided thrombin injection: For small iatrogenic femoral AVF (less evidence than for pseudoaneurysm).
• HF management: If high-output HF → optimize medical therapy; consider surgical/endovascular fistula repair.
• Steal syndrome management: Distal revascularization interval ligation (DRIL); proximalization of arterial inflow (PAI); revision using distal inflow (RUDI) - surgical techniques to restore distal perfusion.

---

Q30. Lymphedema

• Lymphedema is chronic tissue swelling (edema) due to impaired lymphatic drainage, resulting in accumulation of protein-rich interstitial fluid in subcutaneous tissues.
• Unlike other forms of edema (transudates), lymphedema fluid is protein-rich (exudate) → progressive fibrosis and adipose tissue deposition → non-pitting, irreversible edema.

• Normal lymphatics: Transport ~2-4 L/day of protein-rich fluid from interstitium back to circulation via thoracic duct.
• Lymphatic obstruction/insufficiency → protein-rich fluid accumulates in interstitium → osmotic draw of more water → high-protein edema.
• Elevated protein → chronic inflammation → macrophage and fibroblast activation → subcutaneous fibrosis → hardening (non-pitting) and fatty tissue deposition → permanent structural changes if untreated.
• Secondary infection (cellulitis) → further lymphatic damage → vicious cycle.
• Lymphatic stasis → impaired local immunity → recurrent infections.

• Stage 0 (Latent): Lymphatic damage present but no visible swelling; subclinical impairment.
• Stage I (Reversible/Spontaneously Reversible): Soft pitting edema; improves overnight with elevation; no skin changes yet; early.
• Stage II (Non-spontaneously Reversible): Pitting edema that does NOT reduce with elevation alone; skin changes begin; early fibrosis.
• Stage III (Lymphostatic Elephantiasis): Non-pitting, very firm edema; gross limb enlargement; severe skin changes; verrucous/warty skin; papillomatosis; grossly deformed limb.

• Limb heaviness, fullness, tightness.
• Decreased limb mobility/flexibility.
• Recurring skin infections (cellulitis, lymphangitis).
• Aching or pain.
• Psychosocial distress; altered body image.
• Fatigue.

• Pitting edema (early stages) → Non-pitting edema (later): As fibrosis develops.
• Stemmer's sign (pathognomonic of lymphedema): Inability to pinch a fold of skin at the base of the second toe (or finger); skin thickening makes it impossible to lift and fold the skin; positive Stemmer's sign = lymphedema until proven otherwise; negative = normal or other type of edema.
• Limb asymmetry: Measure circumference at multiple standardized points; volume calculated.
• Dorsal foot/hand involvement: Lymphedema characteristically involves the dorsum of the foot/hand (gives "buffalo hump" appearance of dorsum of foot); compared to cardiac edema which does NOT involve dorsum and pits freely; phlebo-lymphedema (CVI + lymphedema) may involve both.
• Skin changes:
  • Hyperkeratosis: Thickened, rough skin.
  • Papillomatosis: Warty, cobblestone skin (late stage).
  • Peau d'orange: "Orange peel" appearance.
  • Fissures, cracks in skin: Entry point for bacteria → cellulitis.
  • Cobblestoning of skin surface.
  • Eczema.
• Lymphorrhea: Leakage of lymph fluid through skin; wet, clear/milky discharge.
• Loss of skin folds: Ankle crease obliterated.

• Clinical assessment: History, examination, Stemmer's sign, limb volume measurement (tape circumference at standardized points every 4 cm; calculate volume by formula; perometry device).
• Duplex venous ultrasound: Exclude CVI and DVT as cause of edema; assess co-existing venous disease.
• Lymphoscintigraphy (radionuclide lymphangiography): Gold standard for confirming lymphatic dysfunction; radiolabeled colloid injected into web spaces → nuclear scan shows lymphatic drainage pattern; delayed or absent tracer uptake = lymphatic dysfunction; quantifies drainage rate; best for diagnosis in difficult cases.
• MRI Lymphangiography (MRL): Detailed anatomical imaging of lymphatic vessels; gadolinium-enhanced or non-contrast; best for surgical planning; identifies dilated lymphatics, collaterals, lymph nodes.
• Indocyanine green (ICG) fluorescent lymphangiography: Near-infrared fluorescence imaging after ICG injection; shows dermal backflow (lymphatic hypertension) in real time; most sensitive for early lymphedema; guides surgical treatment.
• CT scan: Assess soft tissue changes; honeycomb pattern in subcutaneous tissue on CT = characteristic of lymphedema; rule out malignancy causing secondary lymphedema.
• Bioimpedance spectroscopy (BIS): Measures extracellular fluid; L-Dex score; useful for early detection of breast cancer-related lymphedema (preclinical); increasingly used in surveillance post-mastectomy.
• D-dimer, CBC, BNP, albumin, TSH, urinalysis: To exclude other causes of edema.

• Two-phase approach:
  • Phase I (Intensive/Decongestion): Daily sessions with certified lymphedema therapist; 2-4 weeks.
    • Manual lymphatic drainage (MLD): Specialized massage technique; redirects lymph flow to functioning lymphatic pathways; performed by trained therapist; stimulates lymphangion contractions.
    • Multi-layer compression bandaging: Non-elastic short-stretch bandages; reduces limb volume.
    • Remedial exercise: With bandages; stimulates calf muscle pump.
    • Meticulous skin care: Prevent infection; moisturize; treat fungal infections.
  • Phase II (Maintenance/Self-management): Long-term; patient-performed.
    • Compression garments (medical grade): 30-40 mmHg or higher; worn during day; replaced every 3-6 months.
    • Self-MLD.
    • Self-bandaging.
    • Exercise with compression.
    • Daily skin care.

• Flat-knit vs. circular-knit compression garments.
• Custom-fitted for lymphedema (vs. off-shelf for CVI).
• Adjustable compression wrap systems (Velcro-based, e.g., JoViPak, FarrowWrap): Better for patients with dexterity issues.
• Pneumatic compression pump: Multi-chamber sequential pneumatic devices; useful adjunct; use after MLD, not instead of it.

• No drug cures lymphedema.
• Antibiotics: IV or oral penicillin/amoxicillin for cellulitis; long-term prophylactic antibiotics (penicillin V 250 mg BID) for recurrent cellulitis (>2 episodes/year).
• Diuretics: Generally ineffective and potentially harmful in lymphedema (protein remains; only water removed); may cause electrolyte imbalances; used cautiously only if significant venous or cardiac component.
• Benzopyrones (coumarin): Stimulate macrophage-mediated proteolysis; reduce protein load; used in some countries; hepatotoxicity concern.
• Stem cell and anti-VEGF therapies: Experimental.

• Reserved for select patients with debilitating lymphedema not responsive to CDT.
• Physiological (lymphatic reconstruction):
  • Vascularized lymph node transfer (VLNT): Lymph nodes with their blood supply transplanted to affected limb; restore lymphatic function; commonly used for breast cancer-related arm lymphedema; donor sites: inguinal, thoracic, cervical, supraclavicular nodes.
  • Lymphovenous anastomosis (LVA) / Lymphaticovenular anastomosis: Microsurgical connection of lymphatic channels to adjacent venules; bypasses obstruction; best results in early stages with patent lymphatics; minimally invasive.
  • Combined: LVA + VLNT for more severe cases.
• Debulking procedures (reductive):
  • Modified Charles procedure: Radical excision of skin and subcutaneous tissue + skin grafting; for very advanced elephantiasis; non-physiological; last resort.
  • Suction-assisted protein lipectomy (SAL/liposuction): Removes excess fat that has replaced lymphedematous tissue; requires lifelong compression post-operatively; very effective for non-pitting stage II-III lymphedema; does not restore lymphatic function.

• Filariasis: Anti-helminthic treatment: Diethylcarbamazine (DEC) + albendazole; kills microfilariae; does not reverse existing damage; CDT for the edema.
• Pediatric lymphedema (Milroy's disease): CDT adapted for children; compression garments; regular physiotherapy.
• Cancer-related lymphedema: Integrated management with oncology team; breast cancer rehab; surgical reconstruction options.
• Prevention post-mastectomy: Sentinel lymph node biopsy (SLNB) instead of ALND when possible (SLNB: ~5% lymphedema vs. ALND: ~20-30%); immediate lymphatic reconstruction (ILR) at time of ALND; surveillance with BIS; early intervention if detected.

---

CADM - Q29 & Q30 (Detailed Re-answer)

Reference: Bates' Guide to Physical Examination and History Taking, Lynn S. Bickley, 13th Edition, 2023

---

Q29. Arteriovenous Fistula - Etiology, Symptoms and Signs, Differential Diagnosis, Complications, Diagnostic Procedures, etc.

• An arteriovenous fistula (AVF) is an abnormal, direct communication between an artery and a vein that bypasses the normal capillary bed.
• Results in high-pressure, high-velocity arterial blood flowing directly into the low-resistance venous system.
• Can be congenital or acquired; localized or diffuse.

---

• Result of defective embryological vascular development; failure of proper differentiation of arterial and venous channels.
• Part of a broader spectrum of arteriovenous malformations (AVMs).
• Hereditary Hemorrhagic Telangiectasia (HHT / Osler-Weber-Rendu disease):
  • Autosomal dominant; mutations in ENG (endoglin - HHT1) or ACVRL1 (ALK1 - HHT2).
  • Multiple AVMs in lungs (most dangerous - causes paradoxical embolism, hemoptysis), liver (high-output HF), brain (hemorrhagic stroke), GI tract (GI bleeding), nasal mucosa (recurrent epistaxis).
• Klippel-Trenaunay syndrome: Port-wine stain + varicose veins + limb hypertrophy; venolymphatic malformation component.
• Parkes-Weber syndrome: Like Klippel-Trenaunay but with AVMs causing limb hypertrophy + pulsatile varicosities.
• Isolated congenital AVF: Any limb; may not manifest until childhood or adulthood.

• Penetrating trauma: Stab wounds, gunshot wounds, shrapnel → simultaneous injury to adjacent artery and vein → direct communication forms.
• Blunt trauma: Fracture fragments lacerate adjacent artery and vein.
• Common sites of traumatic AVF:
  • Femoral vessels (groin area) - most common site overall.
  • Carotid artery and internal jugular vein (neck trauma).
  • Subclavian vessels.
  • Brachial vessels (arm trauma).
  • Radial artery and adjacent vein.
  • Vertebral artery and vertebral vein.
  • Iliac vessels.

• Post-cardiac catheterization / percutaneous coronary intervention (PCI): Femoral artery access → needle/sheath injury to adjacent femoral vein → AVF; incidence ~0.1-0.3% of femoral access procedures.
• Post-arterial blood gas / arterial line placement.
• Post-renal biopsy: Intrarenal AVF; most common cause of renal AVF; 15-18% incidence after biopsy; usually small, self-limiting; rarely hemodynamically significant.
• Post-orthopedic surgery (disc surgery, hip arthroplasty): Damage to adjacent vascular structures.
• Post-thyroid/parathyroid surgery.
• Post-central venous catheterization: Subclavian or internal jugular AVF.
• Surgical creation for hemodialysis access:
  • Cimino-Brescia fistula: Radial artery to cephalic vein (end-to-side or side-to-side) at wrist; most common HD access; preferred "fistula first."
  • Brachial-cephalic fistula: Antecubital fossa; larger, matures faster.
  • Brachial-basilic transposition fistula: Basilic vein transposed to accessible position.
  • PTFE graft (arteriovenous graft/AVG): Prosthetic graft from brachial artery to antecubital vein; when native vein inadequate.

• Ruptured aortic aneurysm into IVC (aortocaval fistula): Rare but dramatic; sudden high-output HF + pulsatile abdominal mass + venous hypertension in lower limbs + continuous abdominal bruit; treated urgently with endovascular stent-graft.
• Ruptured aortic aneurysm into left renal vein.
• Ruptured renal artery aneurysm into renal vein: Intrarenal AVF with hematuria and hypertension.
• Ruptured splenic artery aneurysm into splenic vein.
• Tumor erosion: Malignant invasion of vessel walls; hypervascular tumors (renal cell carcinoma, hepatocellular carcinoma) develop internal AVF connections.
• Infective endocarditis / mycotic aneurysm rupture into adjacent vein.

---

• Arterial blood at high pressure (80-120 mmHg) shunts into low-pressure vein (5-12 mmHg).
• Distal steal phenomenon: Blood preferentially flows into low-resistance fistula → reduced flow to distal capillary bed → distal ischemia.
• Proximal artery dilation: Increased flow rate → turbulent flow → progressive dilation of feeding artery.
• Venous arterialization: Draining vein exposed to high pressure → dilates, becomes tortuous, thick-walled ("arterialized vein").
• Systemic effects (chronic large AVF):
  • Reduced systemic vascular resistance (SVR) → reflex sympathetic activation → tachycardia, sodium and water retention → increased blood volume and cardiac output.
  • Chronic increase in CO → eccentric LV hypertrophy → eventually high-output HF.
  • Compensatory polycythemia in some chronic cases.

---

• Pulsatile mass: At site of fistula if superficial; may be visible and palpable.
• Pain or tenderness: Especially in traumatic or infective AVF.
• Skin warmth: Increased blood flow → warmth over and around fistula.
• Swelling: Local edema from venous hypertension.
• Wound history: Scar from prior trauma, surgery, or catheterization.

• Coldness, pallor, pain in distal limb: Reduced perfusion beyond fistula.
• Paresthesia and weakness: Nerve ischemia.
• Intermittent claudication: Reduced muscular blood supply.
• Digital gangrene / non-healing wounds: In severe steal; most commonly seen with hemodialysis access fistulae where hand ischemia can develop ("dialysis-associated steal syndrome" - DASS).
• Pins and needles (hand): Carpal tunnel-like symptoms from edema + ischemia in HD access.

• Palpitations and dyspnea: High-output state.
• Leg swelling: Venous hypertension distally.
• Fatigue: Reduced effective tissue perfusion.
• Symptoms of heart failure: Orthopnea, PND, edema (if untreated large chronic AVF).

• THRILL (most specific sign):
  • Continuous palpable vibration (buzzing sensation) over fistula.
  • Present in both systole and diastole.
  • Felt as a "cat's purr" or "washing machine" sensation.
  • Pathognomonic of high-flow AVF.
• CONTINUOUS BRUIT (most characteristic auscultatory sign):
  • Machinery-like, continuous bruit; heard in BOTH systole and diastole.
  • Loudest over fistula site; radiates in direction of blood flow.
  • Systolic component is louder; merges without interruption into diastolic.
  • Note: Simple arterial bruits are systolic ONLY; AVF bruit is continuous (persists through diastole) - key distinction.
• ARTERIALIZED VEINS:
  • Draining veins visibly dilated, tortuous, and pulsatile.
  • Veins feel firm and pulsatile (not soft and compressible as normal veins).
  • Venous varicosities may be prominent.
• HYPERDYNAMIC CARDIOVASCULAR SIGNS (large AVF):
  • Tachycardia.
  • Widened pulse pressure (bounding pulse).
  • Hyperdynamic apex beat.
  • Cardiomegaly (in chronic large fistula).
  • Visible neck vein pulsation.
• DISTAL ISCHEMIC SIGNS:
  • Pallor, reduced capillary refill distally.
  • Absent or diminished distal pulses.
  • Reduced ABI or segmental pressures.
  • Skin breakdown, ulceration, gangrene in severe cases.
• LIMB HYPERTROPHY (congenital AVF in children):
  • Increased limb length and girth; bone overgrowth.
  • Excess arterial flow stimulates bone and soft tissue growth.
• NICOLADONI-BRANHAM SIGN (Branham's Bradycardia Sign):
  • Technique: Manually compress the fistula with finger pressure for 30-60 seconds.
  • Result: Sudden reduction in venous return and decrease in low-resistance circuit → CO drops transiently → baroreceptors detect increased BP → reflex vagally mediated bradycardia and rise in blood pressure.
  • Significance: Confirms the fistula is hemodynamically significant; indicates high-flow fistula contributing to increased CO; if bradycardia occurs = positive Branham sign = significant AVF.
  • Reverse on release: Heart rate increases back to baseline.
  • Also causes disappearance of bruit and thrill on compression.
• HEMODIALYSIS ACCESS FISTULA SPECIFIC SIGNS:
  • Bruit over access: Normal continuous machinery bruit; loss of bruit = thrombosis (access failure).
  • Thrill over access: Normal; if thrill disappears = stenosis or thrombosis.
  • Elevated venous pressure during dialysis: Suggests outflow stenosis.
  • Inadequate flow during dialysis (<600 mL/min): Stenosis or thrombosis.
  • Prominent draining vein: Normal maturation sign.
  • Aneurysm formation at needle puncture sites: Common in long-standing access.

---

---

• Most serious systemic complication of large or chronic AVF.
• Mechanism: Large shunt volume → markedly increased preload → ventricular dilation → eventually decompensation.
• Clinical: Cardiomegaly, S3 gallop, pulmonary edema, peripheral edema, exertional dyspnea, orthopnea.
• Cardiac output may be >10-12 L/min (normal ~5 L/min).
• More common in: Proximal AVF (aortocaval), large congenital AVMs, untreated large traumatic AVF, or poorly designed HD access with excessive flow.
• Management: Closure/ligation of AVF is curative; banding (surgical reduction of fistula flow) for HD access; medical HF therapy as bridge.

• Reduces perfusion distal to fistula via "steal."
• Most clinically significant in hemodialysis access patients (10-20% of HD patients develop some degree of steal).
• Spectrum: Hand coolness/numbness → exercise-induced pain → rest pain → ulceration → gangrene.
• Neurological deficits: Peripheral neuropathy from ischemia (median nerve most common in radial-cephalic fistula).
• Treatment: DRIL (distal revascularization interval ligation), PAI (proximalization of arterial inflow), banding of fistula; revision or closure if severe.

• Arterialized venous pressure → limb edema.
• Varicose vein formation (arterialized veins dilate progressively).
• Skin changes: Hyperpigmentation, lipodermatosclerosis, venous ulcers.
• Compartment syndrome (in acute large AVF).
• Limb hypertrophy in congenital pediatric AVF.

• Arterialized veins weaken progressively → risk of rupture → life-threatening hemorrhage.
• Pseudoaneurysm formation at needle puncture sites (HD access) → risk of rupture.
• Aortic fistula into IVC → massive hemorrhage if not treated urgently.

• Proximal to fistula: Artery enlarges progressively from chronic high flow → fusiform aneurysm.
• Venous side: Venous aneurysm from arterialized high pressure.
• Pseudoaneurysm: At needle puncture sites in HD access.

• Mycotic aneurysm superimposed on fistula.
• Infective endocarditis (via bacteremia from infected fistula).
• Septic thrombophlebitis of arterialized draining vein.
• HD access-related bacteremia: Staphylococcus aureus most common; potentially lethal.

• Stenosis (usually at venous anastomosis or draining vein → intimal hyperplasia) → thrombosis → access loss.
• Incidence: Grafts thrombose more than native fistulae.
• Treatment: Thrombectomy (surgical or pharmacomechanical CDT), angioplasty of underlying stenosis.

• Increased pulmonary blood flow from large AVF → progressive pulmonary hypertension.
• Mainly with large central or multiple AVMs (HHT with pulmonary AVMs).

• In HHT patients: Pulmonary AVMs bypass normal pulmonary capillary filter → venous emboli (thrombus, air, bacteria) cross directly to systemic circulation → stroke, brain abscess, systemic septic emboli.
• Pulmonary AVM is a well-recognized cause of cryptogenic stroke in young patients.

• In congenital AVF/AVM in growing children: Excess blood flow stimulates bone growth → affected limb longer → scoliosis, gait abnormalities.

• Aortocaval fistula: Steal from renal arteries → renovascular hypertension, acute renal failure.
• Mesenteric AVF: Steal from gut → mesenteric ischemia.

---

• Identifies fistula location and feeding vessels.
• Venous waveform: Arterialized = pulsatile high-velocity flow in vein (normally low-velocity, non-pulsatile) = diagnostic of AVF.
• Turbulent flow at fistula mouth with color aliasing.
• "Perivascular tissue vibration artifact" on color Doppler: Diffuse color bleeding outside vessel wall = high-velocity turbulent flow; highly specific for AVF.
• Measures volume flow: For HD access adequacy (normal flow >600 mL/min; >1500 mL/min = at risk for high-output failure; flow <500 mL/min = at risk for thrombosis).
• Detects complications: Stenosis (increased peak systolic velocity >2x at stenosis), thrombosis (absent flow), pseudoaneurysm, aneurysm.
• Standard of care for HD access surveillance.

• Three-dimensional anatomic delineation.
• Identifies feeding arteries, nidus (for AVMs), and draining veins.
• Detects complications (aneurysm, stenosis, rupture).
• Evaluates multiple vascular territories simultaneously.
• Excellent spatial resolution; rapid acquisition.
• Limitation: Radiation, contrast nephropathy, less dynamic information than duplex.
• Essential for surgical planning.

• No ionizing radiation; superior soft tissue contrast.
• Time-of-flight (TOF) MRA: For peripheral AVF.
• Dynamic contrast-enhanced (DCE) MRA: Shows early venous filling (hallmark of AVF).
• Preferred for congenital AVMs (Parkes-Weber, HHT) in children and reproductive-age women.
• Limited by metallic implants (pacemakers, some stents).

• Most detailed visualization of AVF anatomy.
• Real-time dynamic assessment of blood flow direction.
• Arterial injection → early venous opacification = AVF confirmed.
• Measures pressure gradients.
• Enables simultaneous endovascular treatment (embolization, stenting).
• Invasive (arterial access, contrast, radiation); reserved for complex cases or pre-intervention planning.
• Best for identifying fistula nidus in complex AVMs.

• Transthoracic echo (TTE): Assesses LV size and function, CO, signs of high-output failure (dilated LV, increased EF initially, then decreased with failure).
• Pulmonary hypertension assessment (TR jet velocity → RVSP).
• Transesophageal echo (TEE): Better for central/thoracic AVF.
• Bubble study (agitated saline contrast echo): In HHT - if bubbles appear on left side within 3-5 beats of RV = pulmonary AVM confirmed (contrast crosses through pulmonary AVM bypassing lung filter). This distinguishes pulmonary AVM from intracardiac shunt (PFO causes bubbles within 1-2 beats).

• Quantification of shunt fraction (pulmonary/systemic flow ratio Qp:Qs).
• Rarely used for peripheral AVF; more for cardiac shunts.

• Assess distal ischemia in steal syndrome.
• TcPO2 on dorsum of hand/foot: <30 mmHg = severe ischemia.

• Segmental blood pressure measurements.
• Ankle-brachial index (ABI) and toe-brachial index (TBI): Assess degree of distal steal.
• HD access flow measurement: Duplex or Transonic dilution method (gold standard for flow measurement in HD access).

• Contrast injection directly into HD access via fistula needles.
• Assesses anatomical patency; identifies stenosis location and degree.
• Performed in angiography suite; enables simultaneous balloon angioplasty or stenting.

• CBC: Anemia (in chronic HD) or polycythemia (some chronic AVF).
• BNP/NT-proBNP: Elevated if high-output HF.
• Renal function: Especially in aortocaval fistula or renal AVF.
• Blood cultures: If infected AVF suspected.
• Genetic testing: For HHT (ENG, ACVRL1 mutations) in appropriate clinical context.

---

• Small iatrogenic femoral or renal post-biopsy AVF: Many close spontaneously (especially if <3 mm); serial duplex surveillance over 4-6 weeks.
• Asymptomatic small congenital AVF in non-critical location.

• Prolonged manual compression (20-30 min) for small post-catheterization femoral AVF.
• Less effective than for pseudoaneurysm; thrombin injection not recommended for AVF (risk of arterial thrombosis).

• Covered stent-graft: Deployed in the artery spanning the fistula opening; excludes fistula while maintaining arterial continuity; preferred for:
  • Femoral AVF post-catheterization.
  • Aortocaval fistula (endovascular aortic stent-graft).
  • Renal, iliac, subclavian AVF.
  • Results: >90% technical success; low recurrence.
• Transcatheter embolization: For congenital AVM nidus or complex tortuous fistulae where stenting impractical.
  • Agents: Coils (stainless steel or platinum microcoils), ONYX (ethylene vinyl alcohol copolymer), n-BCA glue, Amplatzer plugs.
  • Staged embolization for large complex AVMs.
  • Risk: Non-target embolization, skin necrosis, nerve injury.
• Angioplasty + stenting for HD access stenosis: Balloon angioplasty (PTA) of venous outflow stenosis (most common cause of access dysfunction); stenting for elastic recoil.
• Pharmacomechanical thrombectomy + angioplasty: For thrombosed HD access.

• Primary AVF repair: Exposure of fistula → arteriotomy and venotomy repair → primary closure; for simple traumatic AVF; preferred when anatomy favorable.
• Arterial interposition graft: If significant arterial wall damage; vein or PTFE graft.
• Ligation + bypass: Ligate artery and vein at fistula; bypass artery if distal ischemia risk; for complex AVF.
• Quadruple ligation: Ligate artery and vein proximal AND distal to fistula; effectively excludes fistula; only if collateral circulation adequate.
• Staged resection of congenital AVMs: Complex; multidisciplinary approach; embolization then resection.
• HD access surgery:
  • Banding: Reduce fistula flow to treat high-output failure or severe steal; surgical plication of outflow vein.
  • DRIL (Distal Revascularization-Interval Ligation): Creates bypass from proximal artery to artery distal to fistula + ligates artery between fistula and bypass → restores antegrade flow to hand; gold standard for dialysis steal syndrome.
  • PAI (Proximalization of Arterial Inflow): Anastomose inflow to more proximal artery (e.g., from radial to brachial); reduces steal.
  • Access abandonment + new access creation: When all else fails.

• Medical: Diuretics, ACE inhibitors, beta-blockers (as bridge).
• Definitive: Endovascular or surgical closure/banding of AVF → usually reverses HF if LV not permanently damaged.

• Embolization of feeding artery: Coil embolization; effective; prevents paradoxical embolism and hemoptysis; requires follow-up imaging for recanalization.
• All HHT patients should have CT chest to screen for pulmonary AVM.

---

Q30. Lymphedema

• Lymphedema is a chronic, progressive condition of tissue swelling due to impaired lymphatic transport, resulting in accumulation of protein-rich interstitial fluid in subcutaneous tissues.
• Characterized by high-protein edema → chronic inflammation → fibrosis → adipose deposition → permanent structural changes if untreated.
• Distinct from other edemas: Protein-rich nature of the fluid is the defining characteristic; this drives fibrosis and fat deposition in a way that low-protein transudate edema (cardiac, renal) does not.

---

• Congenital Lymphedema (Milroy Disease):
  • Present at birth or within first 2 years of life.
  • Autosomal dominant; mutations in VEGFR3 (FLT4 gene) → absent or non-functional lymphatic endothelial cells.
  • Bilateral lower limb involvement; ankle and foot predominantly; often worse in males.
  • Non-pitting; may be associated with hydrops fetalis.
  • Additional features: Upslanting toenails, prominent veins, papillomatosis.
• Lymphedema Praecox (Most Common, ~70-80% of primary):
  • Onset: Puberty to age 35; most commonly in early adolescence.
  • Female predominance (10:1); strongly estrogen-associated (worsens with menstruation, pregnancy).
  • Usually unilateral lower limb; begins at ankle/foot.
  • Triggered by minor trauma, infection, or appears spontaneously.
  • Meige disease: Familial lymphedema praecox.
• Lymphedema Tarda:
  • Onset after age 35.
  • Represents decompensation of borderline lymphatics under accumulated insults.
  • Must exclude secondary causes carefully.

• Aplasia: Complete absence of lymphatics (most severe; Milroy type).
• Hypoplasia: Reduced number of undersized lymphatic vessels (most common).
• Hyperplasia/Megalymphatics: Dilated, tortuous, incompetent lymphatics; often bilateral.

1. Malignancy-related (most common cause in developed countries):
   • Surgical lymph node dissection:
     • Axillary lymph node dissection (ALND) for breast cancer: ~20-30% incidence of arm lymphedema; most common secondary lymphedema in developed world.
     • Inguinal lymph node dissection: For melanoma, vulvar, penile, gynecological cancers; unilateral lower limb lymphedema.
     • Pelvic lymphadenectomy: Bilateral or unilateral lower limb + genital lymphedema.
   • Tumor infiltration/obstruction of lymph nodes: Direct compression or invasion.
   • Malignant lymphadenopathy (lymphoma, metastatic disease).
2. Radiation therapy:
   • Radiation fibrosis of lymph nodes and vessels.
   • Additive with surgery: Combined ALND + radiation → highest lymphedema risk (~40%).
   • Delayed onset: Months to years after radiation.
3. Filariasis (Wuchereria bancrofti, Brugia malayi, Brugia timori):
   • Most common cause of secondary lymphedema WORLDWIDE.
   • Transmitted by Culex mosquitoes (Wuchereria); Mansonia/Anopheles (Brugia).
   • Endemic: Sub-Saharan Africa, South and Southeast Asia, Pacific Islands, Latin America.
   • Adult worms reside in lymphatics → mechanical obstruction + inflammatory reaction → progressive lymphatic destruction.
   • Microfilaremia: Larval forms circulate in blood (highest at night - nocturnal periodicity).
   • Leads to gross limb enlargement → elephantiasis (lymphostatic elephantiasis).
   • Genital lymphedema: Hydrocele (most common manifestation in men), scrotal lymphedema, chyluria.
   • Global burden: ~120 million people infected; ~40 million with lymphedema/hydrocele.
4. Recurrent Bacterial Lymphangitis / Cellulitis:
   • Recurrent streptococcal or staphylococcal infections → progressive inflammatory damage to lymphatics.
   • Each episode destroys more lymphatic channels → vicious cycle (lymphedema → stasis → infection → more lymphedema).
   • Important to recognize and treat aggressively with prolonged prophylactic antibiotics.
5. Obesity:
   • Mechanical impairment of lymph transport; compression of lymphatics by adipose tissue.
   • Abdominal wall/truncal lymphedema; bilateral lower limb lymphedema.
   • BMI >50: Severely impaired lymphatic function.
   • Difficult to treat without weight loss.
6. Chronic Venous Insufficiency (Mixed Venolymphatic Edema / Phlebolymphedema):
   • Chronic venous hypertension → overwhelms lymphatic capacity (even though lymphatics structurally normal) → secondary lymphatic dysfunction.
   • Combined venous + lymphatic pathology makes treatment challenging.
   • Venous ulcers with secondary lymphedema: Common in elderly.
7. Tuberculosis / Fungal infections: Granulomatous destruction of lymph nodes.
8. Trauma: Disruption of lymphatics; post-surgical.
9. Contact dermatitis / chronic skin inflammation.
10. Factitious lymphedema (Secretan's Syndrome): Self-induced; tourniquet or pressure applied to limb; psychiatric consultation needed.

---

• Normal lymphatic function: Approximately 2-4 L of protein-rich fluid (albumin, globulins) filtered from capillaries into interstitium daily → collected by initial lymphatics → transported via collecting lymphatics (with bicuspid valves + smooth muscle = "lymphangions") → lymph nodes → thoracic duct → left subclavian vein.
• Lymphedema mechanism:
  1. Lymphatic transport capacity reduced (aplasia, fibrosis, obstruction, damage).
  2. Protein-rich fluid accumulates in interstitium (normally cleared by lymphatics; left behind when lymphatics fail).
  3. High oncotic pressure of accumulated protein draws more water → high-protein edema worsens.
  4. Protein in interstitium triggers chronic inflammatory response → macrophage and fibroblast activation → progressive subcutaneous fibrosis.
  5. Adipose hypertrophy: Fibroblasts differentiate into adipocytes → fat deposition adds to non-pitting component.
  6. Stagnant protein-rich fluid = excellent growth medium for bacteria → recurrent cellulitis.
  7. Impaired local immunity: Normal lymphocyte traffic disrupted → reduced immune surveillance.
  8. Chronic inflammation → changes in overlying skin: Hyperkeratosis, papillomatosis.
  9. Progressive: Without treatment, each episode of cellulitis destroys more lymphatics → accelerating progression.

---

• Heaviness and fullness: Most universal complaint; limb feels "leaden."
• Tightness: Skin feels tight, especially after activity or in heat.
• Reduced flexibility and mobility: Difficulty with hand grip, ankle dorsiflexion.
• Aching and discomfort: Not typically sharp pain (unlike DVT or arterial ischemia).
• Recurrent infections (cellulitis): Fever, pain, erythema, warmth; requires antibiotics.
• Lymphorrhea: Leakage of lymph fluid through skin fissures; clear or milky fluid.
• Psychological distress: Significant impact on quality of life, body image, social function, depression.
• Fatigue: From chronic illness and altered mobility.

• Technique: Attempt to pick up and pinch a fold of skin at the base of the second toe (for lower limb lymphedema) or second finger (for upper limb).
• Normal (Stemmer's Negative): Skin can be lifted and pinched easily into a fold.
• Positive Stemmer's Sign: Skin cannot be lifted and pinched into a fold; feels thickened and firmly adherent; the examiner's fingers cannot achieve a fold.
• Significance: Positive = lymphedema until proven otherwise; reflects subcutaneous fibrosis and tissue thickening pathognomonic of lymphedema.
• Note: In early lymphedema or pure cardiac edema, Stemmer's may be negative.
• Invaluable bedside test; distinguishes lymphedema from other forms of edema.

• Lymphedema characteristically involves the dorsum of the foot/toes ("boxy" or "square toe" appearance).
• In cardiac/renal edema: Dorsum of foot is typically spared; edema is mainly pre-tibial/ankle.
• The "square toe" or "sausage toe" appearance: Toes and dorsal foot swollen → hallmark of lymphedema.

• Non-pitting edema (late stages): Fibrotic tissue; press firmly for 30 seconds; no pit forms.
• Limb asymmetry: Measured by circumferential tape at standardized points (every 4 cm) or by water volumetry; >200 mL difference = clinically significant lymphedema (for upper limb).
• Skin changes:
  • Hyperkeratosis: Thickened, rough, dry skin (warty texture).
  • Papillomatosis: Cobblestone, verrucous skin projections; prominent in stage III.
  • Peau d'orange: Dimpled orange-peel skin texture.
  • Skin fissures: Portal of entry for bacteria.
  • Loss of normal skin creases (ankle crease, toe creases obliterated).
  • Hyperpigmentation (from chronic inflammation).
• Lymphorrhea: Weeping of lymph through skin; clear/straw-colored or milky (chylous) fluid.
• Lymphangiosarcoma (Stewart-Treves syndrome): Rare but life-threatening complication of long-standing lymphedema (especially post-mastectomy); purple-blue skin lesions; angiosarcoma arising in lymphedematous tissue; very poor prognosis.

---

---

• Detailed history: Duration, onset, triggers (travel to endemic areas, prior surgery/radiation, family history).
• Examination: Stemmer's sign, limb circumference measurement, skin quality, presence of varicosities.
• Limb volume measurement:
  • Circumferential measurements at standardized 4 cm intervals along limb; calculate truncated cone volume.
  • Water displacement volumetry: Gold standard for volume; impractical clinically.
  • Perometry (infrared optoelectronic): Precise, rapid, reproducible; used in research and clinical surveillance.
  • Normal inter-limb difference: <10% (upper limb) or <10% of total limb volume.

• First-line vascular imaging.
• Excludes DVT and chronic venous insufficiency as alternative or contributing diagnosis.
• Assesses venous reflux (saphenous, perforators).
• Cannot directly visualize lymphatics; negative duplex + clinical lymphedema = lymphedema confirmed.

• Procedure: Subcutaneous or intradermal injection of 99mTc-labeled albumin nanocolloid (or antimony trisulfide colloid) in web spaces of toes/fingers → gamma camera serial imaging over 2-4 hours.
• Normal: Tracer promptly taken up by lymphatics → reaches inguinal/axillary lymph nodes quickly; symmetric.
• Lymphedema findings:
  • Delayed or absent uptake by regional lymph nodes.
  • Dermal backflow pattern: Tracer "leaks" back into dermal lymphatics = characteristic "starburst" pattern on imaging; represents lymphatic hypertension with retrograde filling.
  • Reduced number of lymphatic channels visible.
  • Asymmetric drainage.
  • Absent nodes (aplasia).
• Quantitative: Transport index can be calculated (semi-quantitative grading).
• Advantages: Functional; defines which type of primary lymphedema (aplasia, hypoplasia, hyperplasia); confirms secondary lymphedema.
• Limitations: Limited anatomical detail; cannot guide surgical planning well.

• Non-contrast T2-weighted MRI: Lymphatic fluid appears bright against dark surrounding tissue; visualizes lymphatic vessels directly.
• Gadolinium-enhanced MRL: Gadolinium injected intradermally → enhanced lymphatics visible.
• Shows: Lymphatic vessel anatomy, dilation, tortuosity, collateral lymphatics, lymph node enhancement or absence.
• Applications: Surgical planning for LVA or VLNT; characterizing complex primary lymphedema; identifying lymphatic leaks (chylothorax, chylous ascites).
• Better anatomical detail than lymphoscintigraphy.

• ICG injected intradermally in web spaces → imaged with near-infrared camera.
• Normal: ICG travels in defined linear lymphatic vessels (normal "linear" pattern).
• Lymphedema: "Dermal backflow" (stardust, splash, diffuse patterns) = retrograde filling of dermal lymphatics due to lymphatic hypertension.
• Most sensitive technique for early (subclinical) lymphedema detection.
• Real-time visualization; guides LVA surgery (identifies patent lymphatics for anastomosis).
• Not suitable for deep lymphatics (near-infrared only penetrates ~1-2 cm into tissue).
• Increasing use in intraoperative mapping.

• Characteristic CT appearance of lymphedema: "Honeycomb pattern" in subcutaneous tissue (thickened fibrous septa with fluid between = compartmentalized edema).
• In cardiac/renal edema: Homogeneous increased density of subcutaneous fat (Cobblestone NOT honeycomb pattern).
• Identifies underlying malignancy causing secondary lymphedema (enlarged lymph nodes, primary tumor).
• Detects complications (infection, sarcomatous transformation).
• Differentiates lipedema (CT shows adipose tissue expansion without honeycomb) from lymphedema.

• Measures extracellular fluid (lymphedema fluid is extracellular).
• L-Dex score: Compares affected vs. unaffected limb; L-Dex >7.1 = clinically significant lymphedema in breast cancer patients.
• Most valuable for early/subclinical detection (Stage 0): Can detect changes before visible edema.
• Used in prospective surveillance post-ALND: Baseline measurement → serial follow-up → if L-Dex rises → early intervention before progression.
• Limitations: Less reliable in bilateral lymphedema; affected by hydration, time of day, activity.

• Localwave tissue dielectric constant meter.
• Measures tissue water content at specific skin depth (1.5 mm or 2.5 mm).
• Sensitive early detection tool; used alongside BIS.

• CBC: Eosinophilia (parasitic: filariasis).
• Microfilariae test: Blood film (night blood for Wuchereria bancrofti - nocturnal periodicity); thick film Giemsa stain; immunochromatographic card test for Wuchereria bancrofti antigen.
• Filaria antibody/antigen testing: ELISA.
• Albumin, protein: To exclude hypoalbuminemia.
• TSH: Hypothyroidism exclusion.
• BNP: Cardiac cause.
• Urinalysis: Proteinuria (nephrotic syndrome).
• Genetic testing: VEGFR3 (FLT4) for Milroy disease; FOXC2 for lymphedema-distichiasis syndrome; GATA2 for Emberger syndrome (lymphedema + immunodeficiency + predisposition to MDS/AML).

• For suspected lymphangiosarcoma (Stewart-Treves): Purple-blue skin lesions in chronic lymphedema.
• Not routinely needed for lymphedema diagnosis.

---

• Specific gentle skin massage technique; developed by Dr. Emil Vodder.
• Sequence: Start centrally (clear lymph node basins first, then work peripherally).
• Stimulates lymphangion peristalsis; redirects lymph flow through collateral pathways.
• Pressure: Very light (30-40 mmHg); rhythmic, slow, wave-like strokes; does NOT hurt.
• Distinct from traditional massage (which increases capillary filtration and worsens lymphedema).
• Duration: 45-90 min per session.
• Contraindications: Acute cellulitis (wait until infection resolves; then resume); active malignancy in affected area (debate); DVT; cardiac failure (relative); renal failure (relative).

• Applied after MLD; worn 22-23 hours/day during Phase I.
• Short-stretch (inelastic) bandages: Work with muscle pump; provide high working pressure (with movement) and low resting pressure (at rest); opposite to elastic bandages.
• Multi-layer: Foam padding + multiple layers of short-stretch bandages; graduated pressure (higher distally).
• Advantages: Reduces limb volume; softens fibrotic tissue; prevents re-accumulation after MLD.
• Different from compression stockings: Stockings used in Phase II maintenance (higher resting pressure).

• Active exercises performed while wearing compression bandages.
• Diaphragmatic breathing: Stimulates central lymphatic drainage (thoracic duct empties into left subclavian vein → diaphragm acts as pump).
• Calf raises, ankle pumps, shoulder rolls, arm circles.
• Walking (calf muscle pump most powerful lymphatic driver).
• Hydrotherapy: Water pressure provides compression; gentle buoyancy exercises.

• Daily washing with mild soap; careful drying between toes.
• Moisturizing with non-perfumed cream: Prevents skin cracking (portal for bacteria).
• Antifungal treatment for tinea pedis (fungal foot infection): Predisposes to cellulitis.
• Nail trimming carefully (avoid trauma).
• Sun protection, insect bite prevention.
• Avoid trauma, injections, blood draws in affected limb.

• Flat-knit custom-made compression stockings (preferred in lymphedema): 30-60 mmHg; custom measurements.
• Circular knit: Ready-made; adequate for mild lymphedema (C3) or CVI.
• Worn all waking hours; replaced every 3-6 months (elasticity reduces with washing).
• Gauntlet/glove for hand; sleeve for arm; stocking for leg.
• Nighttime garments: Softer, less rigid; maintain gains made during day.
• Adjustable velcro wraps (JoViPak, FarrowWrap, CircAid): Easier self-application; useful for elderly, arthritic patients, truncal lymphedema.

• Patients taught by CLT to perform modified MLD on themselves.
• Self-bandaging: When garments insufficient for maintaining reduction.

• Multi-chamber sequential pneumatic pumps.
• Provide external compression graduating from distal to proximal.
• Used as adjunct (after MLD; not instead of); best used before garment application.
• Advanced pumps with separate trunk channels (to first clear proximal lymph node basins before compressing limb).
• Avoid simple single-chamber pumps (push edema into proximal trunk without clearing first → edema develops in trunk/genitalia).

• Low-impact aerobic exercise (walking, swimming, cycling): Improve lymphatic drainage via muscle pump and respiratory pump.
• Weight training: Cautiously; progressive introduction; recent RCT (WHEL study) shows weight training is SAFE and beneficial in breast cancer-related lymphedema (contradicts older advice to avoid arm exercise).
• Yoga, tai chi: Diaphragmatic breathing component useful.

• Acute cellulitis: IV penicillinase-resistant penicillin (flucloxacillin) or cephalosporins; vancomycin if MRSA; typically 10-14 days.
• Prophylactic antibiotics: For recurrent cellulitis (≥2 episodes per year); penicillin V 250 mg twice daily for ≥2 years; dramatically reduces recurrence rate; breaks vicious cycle of infection → lymphatic damage → more infection.
• Benzylpenicillin IM (long-acting penicillin depot injection) monthly: In areas where oral compliance is poor.

• Diethylcarbamazine (DEC): Kills microfilariae and some adult worms; standard treatment; may cause severe reactions from dying worms (Mazzotti reaction) if Loa loa co-infection.
• Albendazole: Combined with DEC (or ivermectin in Africa where Loa loa is endemic).
• Ivermectin: Used in Africa (co-endemic with Loa loa; DEC dangerous with high Loa microfilaraemia).
• Mass drug administration (MDA): WHO program for filariasis elimination; annual treatment of entire at-risk populations.
• CDT still required for lymphedema even after parasites cleared.

• Diuretics: Generally NOT recommended in pure lymphedema; remove water but not protein; protein concentration rises → increased osmotic pull → worsens long-term; only used temporarily if significant venous/cardiac component (phlebolymphedema).
• Benzopyrones (coumarin/oxerutins): Stimulate macrophage-mediated proteolysis; modest effect on reducing protein load and volume; available in Europe; hepatotoxicity limits use.
• Selenium: Antioxidant; some evidence for radiation-induced lymphedema.
• Low-level laser therapy (LLLT): FDA-approved for post-mastectomy lymphedema; reduces fibrosis; softens tissues; improves MLD effectiveness; applied before MLD sessions.

• Microsurgical technique (supermicrosurgery: vessels 0.3-0.8 mm).
• Functioning collecting lymphatics identified (ICG lymphangiography pre-operatively) and directly anastomosed to subdermal venules.
• Bypasses downstream obstruction; diverts lymph directly into venous system.
• Best results: Early stage lymphedema (Stage I-IIa); functioning upstream lymphatics; before extensive fibrosis.
• Multiple anastomoses created along limb.
• Minimally invasive: Small incisions under local anesthesia.
• Outcomes: Reduces limb volume 30-50%; reduces cellulitis frequency; some patients reduce compression garment use.
• ICG lymphangiography: Essential for intraoperative lymphatic vessel mapping.

• Microsurgical transplantation of a lymph node flap (lymph nodes + surrounding tissue + blood vessels) to the affected limb.
• Donor sites (most common):
  • Groin (superficial inguinal nodes): Harvested carefully to avoid donor site lymphedema; sentinel node mapping to protect nodes draining the leg.
  • Lateral thoracic chest wall nodes.
  • Submental/cervical nodes (level I): Good for arm lymphedema.
  • Supraclavicular nodes.
  • Omental nodes (laparoscopic harvesting + free flap).
• Recipient sites: Axilla (for arm), inguinal region (for leg), wrist (distal for arm), ankle (distal for leg).
• Mechanism: Transplanted lymph nodes absorb local lymph and "pump" it into restored vascular supply ("lymph node pump" theory) + possible angiogenic factors stimulate new lymphangiogenesis.
• Best results: Moderate stage lymphedema; when LVA not possible (no functioning upstream lymphatics).
• May be combined with breast reconstruction (lymph node transfer + DIEP flap simultaneously).
• Requires lifelong compression post-operatively (adjunct, not replacement for CDT).

• At the time of ALND: Identify and bypass cut lymphatic vessels → immediately anastomose to adjacent veins or transplant nodes.
• Prophylactic; prevents lymphedema development.
• Growing evidence; performed at specialized centers.

• Removes the excess adipose tissue that has replaced the protein-rich edema in non-pitting lymphedema.
• Indication: Non-pitting stage II-III lymphedema where CDT has plateaued; documented adipose component.
• Technique: Tumescent liposuction under general anesthesia; thorough complete suctioning of all compartments.
• CRITICAL: Requires lifelong compression (at least 23 hours/day) post-operatively to prevent re-accumulation of fluid; without compression, lymphedema returns.
• Results: Significant volume reduction (equal to or greater than contralateral limb volume); improved quality of life; reduced cellulitis.
• Does NOT restore lymphatic function; purely reductive.
• Cannot be used in pitting edema (fluid component will reform).

• Radical excision of skin, subcutaneous tissue, and deep fascia of affected limb segment → application of split-thickness skin grafts.
• Last resort for grossly deformed, non-functional limb (Stage III elephantiasis).
• Results: Good volume reduction; poor cosmesis; complications: graft failure, sensory loss, recurrent cellulitis on grafted skin.
• Rarely performed in modern lymphedema management.

• Sentinel lymph node biopsy (SLNB) instead of ALND whenever oncologically safe: Reduces lymphedema from ~20-30% to ~5%.
• Avoid circumferential tourniquet, blood pressure cuffs, IV cannulas, blood draws in at-risk arm (limited evidence but standard precaution).
• Maintain healthy body weight: Obesity is major risk factor.
• Lymphedema-risk education: Pre-operative and post-operative counseling.
• Surveillance with BIS (bioimpedance): Detect subclinical lymphedema → early intervention (ISL Stage 0) before clinical Stage I/II.
• ILR at time of ALND: Growing prevention strategy.
• Exercise: Supervised progressive resistance exercise SAFE and may reduce risk.

• WHO Global Program to Eliminate Lymphatic Filariasis (GPELF): Annual mass drug administration with DEC + albendazole (or ivermectin in Africa).
• Mosquito control: Insecticides, bed nets, environmental management.
• Personal protection: Insect repellent, long sleeves, mosquito nets.
• Morbidity management and disability prevention (MMDP) programs for affected individuals.

---